Anti-Tumor Activities of Bioactive Phytochemicals in Sophora flavescens for Breast Cancer
Identifieur interne : 000883 ( Pmc/Corpus ); précédent : 000882; suivant : 000884Anti-Tumor Activities of Bioactive Phytochemicals in Sophora flavescens for Breast Cancer
Auteurs : Xianjiao Cao ; Qingqing HeSource :
- Cancer Management and Research [ 1179-1322 ] ; 2020.
Abstract
Patients with breast cancer and breast cancer survivors are frequent users of botanicals and their bioactive phytochemicals. In China, active ingredients in
Url:
DOI: 10.2147/CMAR.S243127
PubMed: 32161498
PubMed Central: 7051174
Links to Exploration step
PMC:7051174Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Anti-Tumor Activities of Bioactive Phytochemicals in <italic>Sophora flavescens</italic> for Breast Cancer</title><author><name sortKey="Cao, Xianjiao" sort="Cao, Xianjiao" uniqKey="Cao X" first="Xianjiao" last="Cao">Xianjiao Cao</name><affiliation><nlm:aff id="AFF0001"><institution>The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250011</addr-line>,<country>People’s Republic of China</country></nlm:aff></affiliation></author><author><name sortKey="He, Qingqing" sort="He, Qingqing" uniqKey="He Q" first="Qingqing" last="He">Qingqing He</name><affiliation><nlm:aff id="AFF0002"><institution>Department of Thyroid and Breast Surgery, The 960th Hospital of the PLA Joint Logistics Support Force</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250031</addr-line>,<country>People’s Republic of China</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">32161498</idno><idno type="pmc">7051174</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051174</idno><idno type="RBID">PMC:7051174</idno><idno type="doi">10.2147/CMAR.S243127</idno><date when="2020">2020</date><idno type="wicri:Area/Pmc/Corpus">000883</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000883</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Anti-Tumor Activities of Bioactive Phytochemicals in <italic>Sophora flavescens</italic> for Breast Cancer</title><author><name sortKey="Cao, Xianjiao" sort="Cao, Xianjiao" uniqKey="Cao X" first="Xianjiao" last="Cao">Xianjiao Cao</name><affiliation><nlm:aff id="AFF0001"><institution>The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250011</addr-line>,<country>People’s Republic of China</country></nlm:aff></affiliation></author><author><name sortKey="He, Qingqing" sort="He, Qingqing" uniqKey="He Q" first="Qingqing" last="He">Qingqing He</name><affiliation><nlm:aff id="AFF0002"><institution>Department of Thyroid and Breast Surgery, The 960th Hospital of the PLA Joint Logistics Support Force</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250031</addr-line>,<country>People’s Republic of China</country></nlm:aff></affiliation></author></analytic><series><title level="j">Cancer Management and Research</title><idno type="eISSN">1179-1322</idno><imprint><date when="2020">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><title>Abstract</title><p>Patients with breast cancer and breast cancer survivors are frequent users of botanicals and their bioactive phytochemicals. In China, active ingredients in <italic>Sophora flavescens</italic> like matrine (MT), oxymatrine (OMT), other <italic>Sophora flavescens</italic> alkaloids and Compound Kushen Injection (CKI) are extensively used for multiple malignant tumors. In vivo and in vitro studies have confirmed that these activities or injection have significant effects on relieving symptoms, alleviating side effects after chemotherapy and improving the quality of life of breast cancer patients, where there is evidence for efficacy. A large number of experimental studies have also revealed that they can inhibit the proliferation, invasion and migration of breast cancer cells according to different mechanisms. This provides promising valuable supportive therapies for prevention, treatment and postoperative recovery of breast cancer. Rigorous clinical research and experimental studies reflect integrative care as it is used in hospital is needed to responsibly move this field forward. This review summarizes an up to date knowledge of the available bioactive phytochemicals, their discovery, current clinical and experimental status.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Manag Res</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Manag Res</journal-id><journal-id journal-id-type="publisher-id">CMAR</journal-id><journal-id journal-id-type="pmc">cancmanres</journal-id><journal-title-group><journal-title>Cancer Management and Research</journal-title></journal-title-group><issn pub-type="epub">1179-1322</issn><publisher><publisher-name>Dove</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">32161498</article-id><article-id pub-id-type="pmc">7051174</article-id><article-id pub-id-type="publisher-id">243127</article-id><article-id pub-id-type="doi">10.2147/CMAR.S243127</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Anti-Tumor Activities of Bioactive Phytochemicals in <italic>Sophora flavescens</italic> for Breast Cancer</article-title><alt-title alt-title-type="running-authors">Cao and He</alt-title><alt-title alt-title-type="running-title">Cao and He</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Xianjiao</given-names></name><xref ref-type="aff" rid="AFF0001">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-2159-1976</contrib-id><name><surname>He</surname><given-names>Qingqing</given-names></name><xref ref-type="corresp" rid="AN0001"></xref><xref ref-type="aff" rid="AFF0002">2</xref></contrib><aff id="AFF0001"><label>1</label><institution>The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250011</addr-line>,<country>People’s Republic of China</country></aff><aff id="AFF0002"><label>2</label><institution>Department of Thyroid and Breast Surgery, The 960th Hospital of the PLA Joint Logistics Support Force</institution>,<addr-line>Jinan</addr-line>,<addr-line>Shandong</addr-line><addr-line>250031</addr-line>,<country>People’s Republic of China</country></aff></contrib-group><author-notes><corresp id="AN0001">Correspondence: Qingqing He <institution>Department of Thyroid and Breast Surgery, The 960th Hospital of the PLA Joint Logistics Support Force</institution>, <addr-line>No. 25 Shifan Road</addr-line>, <addr-line>Jinan</addr-line>, <addr-line>Shandong</addr-line><addr-line>250031</addr-line>, <country>People’s Republic of China</country><phone>Tel +86 13789828035</phone><fax>Fax +86 531666673</fax> Email heqingqing@yeah.net</corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>2</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><volume>12</volume><fpage>1457</fpage><lpage>1467</lpage><history><date date-type="received"><day>20</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2020</year></date></history><permissions><copyright-statement>© 2020 Cao and He.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Cao and He.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><abstract><title>Abstract</title><p>Patients with breast cancer and breast cancer survivors are frequent users of botanicals and their bioactive phytochemicals. In China, active ingredients in <italic>Sophora flavescens</italic> like matrine (MT), oxymatrine (OMT), other <italic>Sophora flavescens</italic> alkaloids and Compound Kushen Injection (CKI) are extensively used for multiple malignant tumors. In vivo and in vitro studies have confirmed that these activities or injection have significant effects on relieving symptoms, alleviating side effects after chemotherapy and improving the quality of life of breast cancer patients, where there is evidence for efficacy. A large number of experimental studies have also revealed that they can inhibit the proliferation, invasion and migration of breast cancer cells according to different mechanisms. This provides promising valuable supportive therapies for prevention, treatment and postoperative recovery of breast cancer. Rigorous clinical research and experimental studies reflect integrative care as it is used in hospital is needed to responsibly move this field forward. This review summarizes an up to date knowledge of the available bioactive phytochemicals, their discovery, current clinical and experimental status.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>breast cancer</kwd><kwd><italic>Sophora flavescens</italic></kwd><kwd>CKI</kwd><kwd>matrine</kwd><kwd>oxymatrine</kwd></kwd-group><funding-group><funding-statement>This work was supported by grants from the President Funding of Jinan Military General Hospital of PLA (Grants 2016ZD02 and 2018ZX01).</funding-statement></funding-group><counts><table-count count="1"></table-count><ref-count count="108"></ref-count><page-count count="11"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="S0001"><title>Introduction</title><p>Application of botanicals to treat solid tumors all over the world has a long history. Many anti-cancer agents have been identified from botanicals, although most of their anti-tumor mechanisms are under discussion. Botanicals are widely used in combination with radiotherapy or chemotherapy to improve the curative efficacy of cancer and reduce complications and side effect. Traditional Chinese Medicine (TCM), including herbal remedies, has been practised for more than five thousand years and many of the herbal medicines have been intensively investigated. In China, TCM formulas are extensively used for modulating immune function and improving the quality of life of cancer patients who undergoing chemotherapy or radiotherapy.<xref rid="CIT0001" ref-type="bibr">1</xref> Because of the low toxicity and wide range of biological activities of botanicals, many natural products have been applied as alternative treatments for many cancers including breast cancer.<xref rid="CIT0002" ref-type="bibr">2</xref></p><p>Breast cancer is the most common noncutaneous malignancy among women worldwide, and the cure and prevention of cancer effects of botanicals are more and more thought highly of now. Although the mortality rate of breast cancer is decreasing and survival rate is increasing year by year, it is also estimated that more than 1000 thousand women are newly diagnosed with breast cancer each year worldwide and that over 400,000 cases will die from breast cancer. China National Cancer Center announced that the incidence of breast cancer is about 34,000 in 2015; Breast cancer accounted for 17.10% of all cancers and was the fifth leading cause of death in female malignant tumors, accounting for 8.16% of all cancer deaths. It has been a serious burden for societies of China and the whole world for a long time. The main treatment options for breast cancer cases include surgery, chemotherapy, hormone and immunological therapy, radiotherapy. Multidrug chemotherapy can reduce the recurrence rate while increase multidrug resistance. Even treated at an early stage, approximately 30% of breast cancer patients suffer from metastasis and relapse. Resistance to chemotherapy and subsequent recurrence and metastasis are two main intractable problems in most patients with breast cancer, which made patients bear additional economic and spiritual stress. The high toxicity of the treatments of breast cancer to normal tissues is practically inevitable. Seeking for effective and safe treatment strategies for breast cancer is an urgent task for medical researchers.<xref rid="CIT0003" ref-type="bibr">3</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref></p><p>In the past several decades, many botanicals are used for breast cancer treatment. So far, it has been proved that there are many kinds of herbal extracts that have effects on the treatment of breast cancer, involving various mechanisms, such as Saikosaponin A, Emodin, Sanguisorba, Oridonin, Curcumol, Triptolide, artesunate, cycloartane triterpenoid derivative.<xref rid="CIT0005" ref-type="bibr">5</xref>–<xref rid="CIT0014" ref-type="bibr">14</xref> Breast cancer prevention is equally important for high-risk women with older age and postmenopause status. Glycyrrhiza Species (Licorice) and its three medicinally used species of licorice (G. glabra, G. uralensis, and G. inflata), Silybum marianum (Milk Thistle) and its extract silibin B or silymarin, Angelica sinensis (Dong Quai) and its dong quai’s phytoconstituents ferulic acid or Z-ligustilide, Epimedium, ginger, black cohosh and flaxseed have been reported for breast cancer prevention. These botanicals and their bioactive phytochemicals play the role of breast cancer prevention through four major mechanisms including hormonal, chemical, inflammatory, and epigenetic.<xref rid="CIT0015" ref-type="bibr">15</xref> Vinca alkaloids and taxol are two anticancer drugs extracted from naturally occurring compounds; however, toxic side effects place restrictions on their use. Therefore, developing novel natural with low toxicity and high therapeutic selectivity is clinically important. Novel molecular markers and genetic mutations are now comprehensively identified in breast cancer genome sequencing projects. At present, most studies on the underlying mechanisms of botanicals on breast cancer are limited to the molecular level, and the role of traditional medicine in gene level is less studied.</p></sec><sec id="S0002"><title>Sophora flavescens</title><p>Kushen (Radix Sophorae Flavescentis/<italic>Sophorae flavescens</italic>), a traditional Chinese herbal medicine, is the dried root of <italic>Sophora flavescens</italic> Ai. In 200 A.D., Kushen was described in the traditional Chinese book <italic>Shen Nong Ben Cao Jing</italic> for the first time and it was used to treat inflammation, solid tumors, and other compounds. The main chemical components in Kushen include alkaloids, flavonoids, alkylxanthones, quinones, triterpene glycosides, fatty acids, and essential oils. Among them, Kushen alkaloids (KS-As) account for 3% and Kushen flavonoids (KS-Fs) account for 1.5%, which are two characteristic components of Kushen. MT and OMT consist of approximately 20% of the total alkaloids in Kushen. <italic>Sophora flavescens</italic> water decoction recorded in <italic>Chinese Pharmacopoeia</italic> can treat diseases such as leukorrhea, jaundice, enteritis, scabies, dysentery, carbuncles as well as pyogenic infections of the skin. KS-As or KS-Fs preparations from different manufacturers are more or less different, but their anti-tumor function was consistent with that in published reports.</p><p>Looking for the active substances is a critical approach to the development of new drugs to treat cancers. As unique tetracyclo-quinolizidine alkaloids, MT and OMT are found only in Sophora species thus far. Various patents of Kushen extracts have been applied in China, USA and other countries.<xref rid="CIT0016" ref-type="bibr">16</xref> In 2005, Kushen extracts were approved by the Chinese FDA for malignant tumor treatment. Kushen alkaloids are effective anticancer drugs and widely used in cancer treatment in China now. The mechanism of breast cancer treatment and prevention includes inhibition of cell proliferation, induction of cell differentiation or apoptosis, ant-inflammatory, antioxidant, and anti-angiogenesis. This literature will introduce the anti-cancer effects of CKI and other phytochemicals extracted from <italic>Sophora flavescens</italic> (<xref rid="T0001" ref-type="table">Table 1</xref>).<table-wrap id="T0001" orientation="landscape" position="float"><label>Table 1</label><caption><p>General Information of Active Ingredients in <italic>Sophora flavescens</italic> for Breast Cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Chemical Formula</th><th rowspan="1" colspan="1">Types of Cancer Cells</th><th rowspan="1" colspan="1">Optimum Experimental Concentration</th><th rowspan="1" colspan="1">Effects</th><th rowspan="1" colspan="1">Side Effects</th><th rowspan="1" colspan="1">Molecular Weight</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Compound Kushen Injection</td><td rowspan="1" colspan="1">Include MT, OMT, sophoridine and oxysophocarpine, et al</td><td rowspan="1" colspan="1">MDA-MB-231, MCF-7</td><td rowspan="1" colspan="1">2 mg/mL</td><td rowspan="1" colspan="1">Reduce cell migration, induce cell apoptosis, reduce energy consumption, anti-angiogenesis, overcome the multidrug resistance, improve the efficiency of chemotherapy, reduce adverse reactions of chemotherapy</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">N</td></tr><tr><td rowspan="1" colspan="1">Matrine</td><td rowspan="1" colspan="1">C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O</td><td rowspan="1" colspan="1">Bcap-37, MCF-7/ADR, BT-474, MDA-MB-231, 4T1</td><td rowspan="1" colspan="1">In vivo: 10mg/Kg<break></break>In vitro: 50–100 μg/mL</td><td rowspan="1" colspan="1">Induce apoptosis of cells, inhibit the tumor vascular formation, protect liver function of breast cancer patients undergoing chemotherapy, down-regulate expression level of miRNA</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">248.36g/mol</td></tr><tr><td rowspan="1" colspan="1">Oxymatrine</td><td rowspan="1" colspan="1">C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub></td><td rowspan="1" colspan="1">MCF-7, MDA-MB-231</td><td rowspan="1" colspan="1">100 μg/mL</td><td rowspan="1" colspan="1">Induce apoptosis of cells, inhibit epithelial-mesenchymal transformation of cells</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">264.37g/mol</td></tr><tr><td rowspan="1" colspan="1">kurarinone</td><td rowspan="1" colspan="1">C<sub>26</sub>H<sub>30</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">MDA-MB-453S, MCF-7, Bcap-37</td><td rowspan="1" colspan="1">7.3 and 31 µg/mL</td><td rowspan="1" colspan="1">Enhance antitumor activities of taxol, suppress cell proliferation</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">438.52 g/mol</td></tr><tr><td rowspan="1" colspan="1">2ʹ-methoxy-kurarinone</td><td rowspan="1" colspan="1">C<sub>27</sub>H<sub>32</sub>O<sub>6</sub></td><td rowspan="1" colspan="1">MDA-MB-453S, MCF-7, Bcap-37</td><td rowspan="1" colspan="1">7.3 and 31 µg/mL</td><td rowspan="1" colspan="1">Enhance antitumor activities of taxol, suppress cell proliferation</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">452.55g/mol</td></tr><tr><td rowspan="1" colspan="1">Sophoridine</td><td rowspan="1" colspan="1">C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O</td><td rowspan="1" colspan="1">MCF-7</td><td rowspan="1" colspan="1">30µg/mL</td><td rowspan="1" colspan="1">Antiproliferative activity</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">248.37g/mol</td></tr><tr><td rowspan="1" colspan="1">Sophoridine+COCH<sub>2</sub>Br</td><td rowspan="1" colspan="1">C<sub>17</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub>Br</td><td rowspan="1" colspan="1">MCF-7</td><td rowspan="1" colspan="1">20µg/mL</td><td rowspan="1" colspan="1">Antiproliferative activity, suspend the cell cycle</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">370.31g/mol</td></tr><tr><td rowspan="1" colspan="1">9-methylanthracene+CH<sub>2</sub>OH</td><td rowspan="1" colspan="1">C<sub>16</sub>H<sub>2</sub>O</td><td rowspan="1" colspan="1">MCF-7/AMD</td><td rowspan="1" colspan="1">1.25–5.0µg/mL</td><td rowspan="1" colspan="1">Block cell cycle</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">210.19 g/mol</td></tr><tr><td rowspan="1" colspan="1">12-N-p-Chlorobenzyl sophoridinic-4ʹ,4- chlorophenyl ketone</td><td rowspan="1" colspan="1">C<sub>28</sub>H<sub>34</sub>ON<sub>2</sub>Cl<sub>2</sub></td><td rowspan="1" colspan="1">MCF-7/AMD</td><td rowspan="1" colspan="1">1.25–5.0µg/mL</td><td rowspan="1" colspan="1">Block cell cycle</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">485.50 g/mol</td></tr><tr><td rowspan="1" colspan="1">−4ʹ-4ʹ-diethyl sophoridinene bihydrochloride</td><td rowspan="1" colspan="1">C<sub>26</sub>H<sub>39</sub>N<sub>2</sub>Cl·2HCl</td><td rowspan="1" colspan="1">MCF-7/AMD</td><td rowspan="1" colspan="1">1.25–5.0µg/mL</td><td rowspan="1" colspan="1">Block cell cycle</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">486.98g/mol</td></tr><tr><td rowspan="1" colspan="1">Matrine+ methyl 6‑bromo‑2‑naphthoate</td><td rowspan="1" colspan="1">C<sub>26</sub>H<sub>9</sub>N<sub>2</sub>O<sub>2</sub>Br</td><td rowspan="1" colspan="1">BT-20, MCF-7</td><td rowspan="1" colspan="1">12.5, 25, 50 µM</td><td rowspan="1" colspan="1">Induce apoptosis and oxidative stress</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">461.27 g/mol</td></tr><tr><td rowspan="1" colspan="1">5,7,D, 2ʹ,4ʹ-tetrahydroxy-8-lavandulylflavano</td><td rowspan="1" colspan="1">C<sub>25</sub>H<sub>28</sub>O6</td><td rowspan="1" colspan="1">MDA-MB-231</td><td rowspan="1" colspan="1">0-30µM</td><td rowspan="1" colspan="1">Increase cell apoptosis</td><td rowspan="1" colspan="1">Unclear</td><td rowspan="1" colspan="1">423.18 g/mol</td></tr></tbody></table></table-wrap></p></sec><sec id="S0003"><title>Compound Kushen Injection</title><p>Compound Kushen Injection (CKI), commonly known as the Yanshu Injection, is exacted from Kushen (Radix Sophorae Flavescentis). The chemical fingerprint of CKI contains at least 8 different components, with primary 4 principles including MT, OMT, sophoridine and oxysophocarpine, which exhibit a variety of pharmacological activities. In China, CKI has been extensively used integrated with both TCMs and modern medicines when treating tumors, including cardiovascular and rheumatic diseases as well as viral hepatitis. CKI was approved for the treatment of cancer by the State Food and Drug Administration of China more than 20 years ago. Since 1995, it has been widely used to treat liver cancer, nonsmall cell lung carcinoma, and gastric cancer and acute leukaemia in combination with other antitumor drugs like cisplatin, vinorelbine et al.<xref rid="CIT0017" ref-type="bibr">17</xref>–<xref rid="CIT0021" ref-type="bibr">21</xref> Experimental and clinical research has shown that CKI and its compounds exhibit anti-cancer actions, such as inhibiting cancer cell proliferation, metastasis and invasion, accelerating cell apoptosis, inducing cell differentiation and cycle arrest, restraining angiogenesis, reversing multidrug resistance, and reducing chemotherapy-induced toxicity. In China, the study of CKI is mostly focused on clinical practice. The involvement of CKI and its mechanisms of breast cancer treatment are reviewed below.</p><p>Uncontrolled migration of cells away from the primary tumor leads to cancer progression, which is the main cause of cancer-related deaths. Reconstitution and fractionation of CKI highlight the importance of combinations of multiple compounds for antitumor activity. Live-cell imaging confirmed CKI strongly reduced the migration of MDA-MB-231 cells, with down-regulation of actin cytoskeletal and focal adhesion genes.<xref rid="CIT0022" ref-type="bibr">22</xref> The cell cycle was identified as the potential primary target pathway of CKI in MCF-7 cells. CKI may induce apoptosis in MCF-7 cells via a p53 independent mechanism; furthermore, lncRNA H19, which over-expressed in breast cancer, was significantly down-regulated in cells treated with CKI.<xref rid="CIT0023" ref-type="bibr">23</xref> In Hep G2 and MDA-MB-231 cells, protein levels in cell cycle pathway, DNA repair pathway and DNA double-strand breaks (DSBs) could be altered by CKI. It declined protein levels for cell cycle and DNA repair while increasing the level of DSBs. At the same time, energy metabolism was reduced because of reduced glucose consumption and cellular energy charge. These results support a model of action of CKI that multiple compounds rather than individual components affect multiple targets and the synergistic.<xref rid="CIT0024" ref-type="bibr">24</xref> Breast cancer stem cells (CSCs) are the sources of oncogenesis, cancer metastasis and relapse. SP cells exhibit properties similar to CSCs because of the capabilities to proliferate more tumorigenic cells than other populations. Compared with cisplatin and saline (as a control) group, CKI suppressed the size of MCF-7 SP population (approximately 90%), and down-regulated the main genes of Wnt signaling pathway to suppress tumor growth, which suggested that CKI may serve as a novel drug targeting CSCs.<xref rid="CIT0025" ref-type="bibr">25</xref> Anti-angiogenesis may be one of the important mechanisms of CKI in inhibiting tumor growth. Different doses of CKI injected into the mice with tumor exhibited different angiogenesis effects: With the increase of compound Kushen injection dose, the tumor mass was decreased significantly, and the tumor inhibition rate was obviously increased.<xref rid="CIT0026" ref-type="bibr">26</xref> Combination of CKI and doxorubicin could overcome the multidrug resistance in breast carcinoma MCF-7 cells. They showed an obvious synergistic effect, with an increase in the accumulation of doxorubicin and reduction of the expression of P-glycoprotein.<xref rid="CIT0027" ref-type="bibr">27</xref> In two animal experiments, CMI could obviously decrease the levels of PDCD4, P53, E2, survivin and Ki67 in the model rats of breast cancer.<xref rid="CIT0028" ref-type="bibr">28</xref>,<xref rid="CIT0029" ref-type="bibr">29</xref></p><p>The detection of the expression level of Survivin was expected to be the predictive index of paclitaxel chemotherapy in breast cancer. For patients with high expression of Survivin, combining with CKI may improve the efficiency of chemotherapy, and even prolong PFS.<xref rid="CIT0030" ref-type="bibr">30</xref> In addition, the serum level of VEGF-A decreased in breast cancer patients treated with CKI during radiotherapy, and the decrease was greater than that treated with radiotherapy alone.<xref rid="CIT0031" ref-type="bibr">31</xref></p><p>CKI is widely used in China. It is often used in combination with operative radiotherapy, chemotherapy and neoadjuvant chemotherapy. The effect is usually better than that of CKI alone, which may be related to improving the immune function of patients.<xref rid="CIT0032" ref-type="bibr">32</xref>–<xref rid="CIT0034" ref-type="bibr">34</xref> Patients with CKI treatment had higher levels of CD3<sup>+</sup>, CD4<sup>+</sup>, CD4<sup>+</sup>/C8<sup>+</sup> and NK cells than those with only postoperative radiotherapy.<xref rid="CIT0035" ref-type="bibr">35</xref>,<xref rid="CIT0036" ref-type="bibr">36</xref> Yasheng et al assessed relevant randomized controlled trials from 2000 to 2017 and the results showed that patients given CKI combined with chemotherapy (therapy group) had a higher performance status improvement rate than that given only chemotherapy (control group). In the analysis adverse drug reactions (ADRs), CKI combined with chemotherapy was indicated to significantly reduce the rate of liver dysfunction, kidney dysfunction, the reaction of fatigue, diarrhea, bone marrow suppression, hair loss, nausea and vomiting, oral mucositis, abnormal elevation of tumor marker CEA and CA153 and platelet decrease.<xref rid="CIT0037" ref-type="bibr">37</xref>–<xref rid="CIT0040" ref-type="bibr">40</xref> Lymphocyte transformation ratio, immunoglobulin level,<xref rid="CIT0041" ref-type="bibr">41</xref> life quality, KPS and QOL score had also been improved.<xref rid="CIT0038" ref-type="bibr">38</xref>–<xref rid="CIT0040" ref-type="bibr">40</xref> What’s more, CKI had a good analgesic effect on bone and muscle pain caused by the paclitaxel chemotherapy for breast cancer patients, with their life quality improvement.<xref rid="CIT0042" ref-type="bibr">42</xref></p><p>But these clinical studies face many problems to be solved urgently. Ongoing challenges include the inability to bind participants to the study, because most measures are subjective, which are susceptible to suggestive biases. Patients who received it may perceive a benefit to the intervention.</p></sec><sec id="S0004"><title>Matrine</title><p>As one of the major quinolizidine alkaloids of <italic>Sophora flavescens</italic>, MT (C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O) is extracted from the root of Kushen. MT has pharmacological effects such as anti-diuretic, anti-asthma, anti-bacterial, anti-inflammatory and immune suppressive activities. What’s more, it has therapeutic effects on cardiac arrhythmia, hepatitis and various solid tumors. For years, MT has been reported to have promising pharmaceutical efficacies for various cancer cells, such as acute myeloid leukaemia, nasopharyngeal Carcinoma, hepatocellular carcinoma, cervical cancer, colorectal cancer, bladder cancer, prostate cancer, pancreatic cancer.<xref rid="CIT0043" ref-type="bibr">43</xref>–<xref rid="CIT0054" ref-type="bibr">54</xref> However, the antitumor function about the molecular mechanism of MT still remains unclear. Like other extracts of botanicals, it has some moderate side effects, such as toxicity to the central nervous, coupled with system low water solubility, bioactivity and bioavailability. Opening of the D-ring and breaking of the amide bond can destroy the anti-proliferative activities, which mean amide bond may be required for the antitumor activities of MT. Annexin A2 has been identified as a direct-binding target of MT in cancer cells using the photo-affinity labeling approach.<xref rid="CIT0055" ref-type="bibr">55</xref></p><p>Autophagy might cooperate, aggravate or antagonize apoptosis.<xref rid="CIT0056" ref-type="bibr">56</xref> MT has been shown to promote autophagic cell death and induce autophagic in cancer cells in recent years. Autophagy was a protective cellular response to MT treatment;<xref rid="CIT0057" ref-type="bibr">57</xref> therefore, inhibition of matrine-induced autophagy by treating the cancer cells with chloroquine enhanced the cytotoxicity. The molecular mechanism of autophagy induced by the effect of MT in human breast cancer Bcap-37 cells may be via down-regulating PI3K/Akt/mTOR signaling pathway.<xref rid="CIT0058" ref-type="bibr">58</xref></p><p>Earlier studies suggest that the mechanism of inhibiting growth and inducing apoptosis of MCF-7/ADR cell growth is related to the blocking of S period cells.<xref rid="CIT0059" ref-type="bibr">59</xref> Bcl-2, a novel anti-cancer target, is commonly associated with breast cancer. When treated with MT, three types of breast cancer cells (MCF-7 cells, BT-474 cells, MDA-MB-231) were all induced to death. The obvious effects on inhibiting the growth of MCF-7 cells and promoting the apoptosis might be achieved by up-regulating the expression of Fas protein, inhibiting telomerase activity, and down-regulating the expression of VEGF protein to inhibit the tumor vascular formation. It displayed synergistic effects with trichostatin A, celecoxib and rosiglitazone against VEGF excretions and the cell proliferation via EGF/VEGF-VEGFR1-Akt-NF-κB signaling pathway. Other studies revealed that the suppression of the cancer cell proliferation and invasion by MT is associated with inhibition of Akt signaling: downstream targets such as Bcl-2/Bax, NF-κB, p-65, MMP-9 and MMP-2, and upstream targets such as EGF, VEGF and VEGFR1 in the breast cancer cells.<xref rid="CIT0060" ref-type="bibr">60</xref> Compared to the controls, tumors treated with MT had a greater apoptosis index and a less microvessel density by downregulating the expression of Bcl-2/Bax, p53, VEGF and VEGFR-2, increasing the activation of caspase-3 and caspase-9.<xref rid="CIT0061" ref-type="bibr">61</xref>–<xref rid="CIT0068" ref-type="bibr">68</xref> In another experimental study, MT inhibited the phosphorylation of AKT level to regulate the downstream apoptosis factors of PI3K/AKT signal pathway; the expressions of MRP1, P-GP, Bcl-2, p-AKT were down-regulated and PTEN level was up-regulated.<xref rid="CIT0069" ref-type="bibr">69</xref> Conversely, in one study, Bax is overexpressed while Bcl-2 expression is decreased: MT inhibited the cell growth and induced apoptosis through up-regulation of Bax and down-regulation of Bcl-2 expression.<xref rid="CIT0070" ref-type="bibr">70</xref> Animal research revealed that MT inhibited the expression of VEGF and downregulated the Wnt/β-catenin signaling pathway in vivo. The 4T1-tumor-bearing mice treated with MT (100 mg/kg) exhibited a significant reduction in tumor volume and weight compared with the control group, and the expression levels of cytochrome c, cleaved caspase-9 and caspase-3 increased significantly.<xref rid="CIT0071" ref-type="bibr">71</xref></p><p>The treatment with MT resulted in the degradation of the inhibitor of κB (IκB) kinase β (IKKβ), which is one of the activation of IkB kinases (IKKs) and results in the phosphorylation of IkB.<xref rid="CIT0072" ref-type="bibr">72</xref> The ER unfolded protein response (UPR) is a cellular signaling pathway in the ER, which is a survival mechanism utilized by tumors to buffer proteotoxic stress; overload ER stress is considered to be a key regulator of tumor cell death pathways in response to anticancer drugs. Endoplasmic reticulum stress is mainly involved in the cell apoptosis induced by MT. It could inhibit mitochondrial activity by promoting the release of cytochrome C and enhancing caspase-3 function to induce ER stress-mediated apoptosis. At the same time, MT inhibits the expression of hexokinase II and glycometabolism to down-regulate energy metabolism in MCF-7 cells.<xref rid="CIT0073" ref-type="bibr">73</xref> The apoptosis induction effect may be caused by reducing mitochondrial transmembrane potential and leaving the MMP channel open.<xref rid="CIT0074" ref-type="bibr">74</xref>,<xref rid="CIT0075" ref-type="bibr">75</xref> What’s more, it may regulate the proliferation and apoptosis of 4T1 cells by inhibiting the expression of ANXA3 mRNA and down-regulating the expression of ANXA3 protein.<xref rid="CIT0076" ref-type="bibr">76</xref></p><p>Recent evidence has indicated that miRNAs can act as mediators of the therapeutic efficacy of botanicals. MiR-21 is overexpressed in the vast majority of cancers such as colorectal cancer, bladder cancer, lung cancer, prostate cancer and breast cancer. Inactivation of PTEN promoted the accumulation of PIP<sub>3</sub>, resulting in phosphorylation of Akt, and this process is related to the high expression level of miR-21. An experimental study showed that MT up-regulated PTEN and down-regulated PTEN p21<sup>/WAF1/CIP1</sup> and p27<sup>/KIP1</sup>, which resulted in the inhibition of cell cycle progression and proliferation. It may inhibit breast cancer cell growth by interfering miR-21/PTEN/Akt signaling pathway.<xref rid="CIT0077" ref-type="bibr">77</xref>,<xref rid="CIT0078" ref-type="bibr">78</xref> Upregulation of ZIC1 gene expression or MT alone can significantly inhibit the proliferation, adhesion and migration of MDA-MB-231 cells, and induce the apoptosis of human breast cancer cells, while the anti-tumor effect of ZIC1 gene combined with MT is more obvious.<xref rid="CIT0079" ref-type="bibr">79</xref></p><p>Breast cancer patients receiving chemotherapy like anthracyclines and taxanes bear severe cumulative toxicities and tolerability disturbance. MT and chemotherapeutic drugs had synergistic effects and it reversed multidrug resistance in breast cancer, which involved regulating the downstream apoptosis factors (Bcl-2, p65, Bax, PARP, GSK-3β, Caspase-3), inhibiting the activation of PI3K/AKT pathway, and reducing P-glycoprotein expression in breast carcinoma MCF-7 cells.<xref rid="CIT0080" ref-type="bibr">80</xref>–<xref rid="CIT0082" ref-type="bibr">82</xref> MT injection has a protective effect on liver function of breast cancer patients undergoing chemotherapy after operation.<xref rid="CIT0083" ref-type="bibr">83</xref> Other types of pharmaceutical preparations of Kushen such as <italic>Sophora flavescens</italic> alkaloid gels also can restrain cancer cell proliferation, inhibit metastasis and induce cellular apoptosis.<xref rid="CIT0084" ref-type="bibr">84</xref> Further clinical studies with different concentrations and types of MT are warranted to obtain a better picture of antitumor activities of it.</p></sec><sec id="S0005"><title>Oxymatrine</title><p>Oxymatrine (molecular formula: C<sub>15</sub>H<sub>24</sub>N<sub>2</sub>O<sub>2</sub>) is another major alkaloid component extracted from the roots of Kushen, which belongs to quinolizidine alkaloid with relative molecular mass of 264.4. OMT has been shown a wide range of pharmacological effects, such as antitumor, anti-hypertension, anti-inflammation, heart strengthening, antipyresis and analgesia, anti-allergy, anti‑arrhythmia, asthma relieving, sedation and hypnosis, inhibition of myocardial ischemia and infarction, antivirus and sterilization. Many in vivo and in vitro experiments suggest that OMT exhibits antineoplastic properties in several cancers via different signaling pathways, including suppression of proliferation and promotion of apoptosis.<xref rid="CIT0085" ref-type="bibr">85</xref></p><p>Previous study had confirmed that the antineoplastic effect of OMT was related to the induction of apoptosis of cancer cells by blocking the process of cell cycle, initiating cell self-regulation procedures.<xref rid="CIT0086" ref-type="bibr">86</xref> A recent study revealed that it involved the inhibition of epithelial-mesenchymal transformation of cancer cells.<xref rid="CIT0087" ref-type="bibr">87</xref> Similarly, one study demonstrated that it induced apoptosis in breast cancer cells by down-regulating apoptosis-related protein, including poly (ADP-ribose) polymerase (PARP) and cleaved Caspase-3, cleaved Caspase-9.<xref rid="CIT0088" ref-type="bibr">88</xref> Like other antiapoptotic proteins (Bcl-XL, Mcl-1, Bcl-W), BCL-2 regulates cell differentiation and apoptosis through the intrinsic (or mitochondrial) pathway. Highest concentration of OMT (100 μg/mL) regulated Bax mRNA abundance by 169% at 72 hrs, and regulated Bax mRNA abundance by 169%, resulting in promoting apoptosis in MCF-7 cells.<xref rid="CIT0089" ref-type="bibr">89</xref> “side-population (SP)” cells, which are used for identification and analysis of the CSCs, show the characteristics of the cancer stem-like cells and represent a population with a capacity of limited maturation and self-renewal. Ying Zhang et al explored the effect of OMT on the SP of MCF-7 cells and this study demonstrated that OMT treatment increased the expression of phosphorylated β-catenin, which is related to the inactivation of Wnt signaling pathway, with the decrease of total β-catenin and deactivation of Wnt signaling pathway. It decreased the viability of MCF-7 cells in a time- and dose-dependent manner. What’s more, compared with cisplatin, OMT showed a lower inhibitory effect on non-SP cells and a higher inhibitory effect on SP cells.<xref rid="CIT0090" ref-type="bibr">90</xref> On the other hand, OM could clearly inhibit the proliferation and increases apoptosis of human MCF-7 cells, and the mechanism of this effect probably related to the activity of Wnt/β-catenin signaling pathway,<xref rid="CIT0091" ref-type="bibr">91</xref>,<xref rid="CIT0092" ref-type="bibr">92</xref> with the expression of downstream cytokines c-myc and cyclinD1 decreasing.</p><p>OM had direct anti-tumor effects and partly reversed MDR. The mechanism of reversing MDR was associated with the behavior of OMT down-regulating P-gP expression on the cell membrane.<xref rid="CIT0093" ref-type="bibr">93</xref> OM enhanced the sensibility of MCF-7 cells to the cytotoxicity of NK-92MI cells, most likely through activating the NF-κB signaling pathway, up-regulating the expression levels of ULBP1, ULBP2 and MICA/B in MCF-7 cells, promoting the secretion of TNF-α and IFN-γ by NK-92MI cells.<xref rid="CIT0094" ref-type="bibr">94</xref></p></sec><sec id="S0006"><title>Other <italic>Sophora flavescens</italic> Alkaloids</title><p>Many flavonoids have been reported antitumor activities through anti-angiogenesis mechanism.<xref rid="CIT0095" ref-type="bibr">95</xref>–<xref rid="CIT0097" ref-type="bibr">97</xref> Those isolated from Kushen have been demonstrated anti-inflammatory, anti-proliferative and antioxidant properties experimentally. Novel flavonoids isolated from S<italic>ophora flavescens</italic> had been identified as more potent antitumor activities than other Kushen alkaloids. 56 different flavonoids have been identified from KS-Fs, among which 21 of the KS-Fs have been described to have antitumor activities in vitro. KS-Fs consisted of kurarinone (Kur, 29%), 2′-methoxy-kurarinone (MeO-Kur,5%), sophoraflavanone G (SFG, 2%) and other flavonoid species. The nonflavonoid compounds consist of alkylxanthones, triterpene glycosides, quinones, essential oils and fatty acids. Recent studies illustrated the antineoplastic effects of novel <italic>Sophora flavescens</italic> alkaloids, including matrine derivative WM622, WM-127, matrine derivatives containing benzo-α-pyrone structure (6aS, 10S, 11aR, 11bR, 11cS)-10-methylamino-dodecahydro-3a,7a-diaza-benzo (de) (MASM), which beared therapeutic potentials for lung and hepatocellular carcinoma.<xref rid="CIT0098" ref-type="bibr">98</xref>–<xref rid="CIT0101" ref-type="bibr">101</xref></p><p>Kur and KS-Fs were able to enhance the effects of Taxol and adriamycin on tumor proliferation in vitro. Either combination of low dose of Taxol (5 mg/kg) or high dose of taxol (5 mg/kg), KS-Fs (200 mg/kg/day) were shown to enhance the effect of Taxol on tumor growth in vivo.<xref rid="CIT0102" ref-type="bibr">102</xref> Other matrine derivatives from sophoridine have also been developed. Many novel N-substituted sophoridinic acid derivatives were synthesized, and their cytotoxicity and anticancer activities were evaluated. An introduction of an aliphatic acyl on the nitrogen might enhance the antitumor activity. Among the synthesized derivatives, COCH<sub>2</sub>Br bearing bromoacetyl side-chain inhibited the activity of DNA topo I to suspend the cell cycle at S-phase, which lead the breast cancer tumor cells to apoptosis.<xref rid="CIT0103" ref-type="bibr">103</xref> A study revealed this (2S)-7,2ʹ,4ʹ-trihydroxy-5-methoxy-8-dimethylallyl flavanone can inhibit proliferation, migration, adhesion, and tube formation of endothelial cells.<xref rid="CIT0104" ref-type="bibr">104</xref> Because of its anti-angiogenesis activity and anti-proliferative properties this new flavonoid can be a good anticancer candidate. New sophoridinol derivatives and N-substituted sophoridinic acid/ester such as sophoridinol 7i (R1:9-methylanthracene, R2:CH2OH) arrest the cell cycle at the G0/G1 phase and showed an antiproliferative activity with an IC50 of 3.1 μM.<xref rid="CIT0105" ref-type="bibr">105</xref></p><p>It is well documented that several quinolizidine alkaloids have potential antitumor activity. A series of 12-chlorobenzyl sophoridinic derivatives with novel chemical scaffolds such as compounds 5a(C7H4OCl-) and 7b (C13H8F2p2-) exhibited reasonable antiproliferative and anticancer activities; they displayed an equipotency in both adriamycin (AMD)-susceptible and resistant MCF-7 breast carcinoma cells.<xref rid="CIT0106" ref-type="bibr">106</xref> In addition, three novel compounds (YF3‑5, YF3‑7 and YF3‑9) all demonstrated anti‑proliferation activity, of which YF3‑5 showed the strongest anti‑proliferation properties against the four human cancer cell lines (BT20 breast, MCF‑7 breast, A549 lung and U2OS osteosarcoma cells).<xref rid="CIT0107" ref-type="bibr">107</xref> Cell cycle arrest and induction of mitochondria-mediated apoptosis are common mechanisms of inhibiting cell proliferation. Recently, sophoraflavanone G (SG), a compound isolated from <italic>Sophora flavescens</italic>, induced reactive oxygen species, DNA fragmentation, nuclear condensation, showing anti-tumor and anti-inflammatory properties in MDA-MB-231. SG increased expression of cleaved caspase-3, caspase-9, caspase-8, and decreased Bcl-2 and Bcl-xL expression, which inhibited the migration and invasion of breast cancer cells.<xref rid="CIT0108" ref-type="bibr">108</xref></p></sec><sec id="S0007"><title>Conclusions and Future Directions</title><p>Traditional medicine, such as Ayurvedic medicine, Chinese medicine, uses unidentified chemical entities with unknown mechanisms of action. TCM has been applied in many countries and regions and has achieved certain results. From the point of view of the basic principles of evidence-based medicine and the provision of clinical scientific evidence, there are still some problems to be solved in the practice of TCM application, such as the lack of sufficient experimental data on the effectiveness and safety of TCM, not an exhaustive study on side effects of TCM. The clinical trials of TCM are short of large sample randomized controlled data and exact evaluation index system and evaluation method in this field.</p><p>This review summarizes multiple anti-cancer effects of active ingredients in <italic>Sophora flavescens</italic>. Effective extracts of medicinal plants, such as MT, OMT and their derivatives, have been extensively studied in breast cancer. There is a growing body of evidence supporting the use of Kushen and its active ingredients as effective supportive care strategies during breast cancer treatment. CKI and other phytochemicals extracted from <italic>Sophora flavescens</italic> may become potential complementary and alternative therapy for breast cancer in the future. In China, patients with breast cancer commonly use them as supportive care during cancer treatment and to manage treatment-related side effects.</p><p>However, evidence supporting the application of MT, OMT and other <italic>Sophora flavescens</italic> alkaloids in the oncology setting is limited. The specific anti-cancer mechanism of them needs further systematic studies. Some of the reported clinical studies about them were not well-controlled studies and not blinded. Although they are perceived as harmless, more studies are needed on safety rather than efficacy. What’s more, little information is available on toxicities and cost effectiveness. Drug-botanical interactions, pharmacokinetic and distribution profile of active constituents have to be determined to help reach safe and efficacious concentrations in clinical settings. Evaluation and exploration of the clinical impact that is more truly generalizable must be made to avoid potentially toxic side effects or loss of activity of active ingredients. Additionally, seeking international cooperation in the research of them is also an important way to promote these compounds more widely used.</p></sec></body><back><ack><title>Acknowledgments</title><p>Authors are thankful to the Department of Thyroid and Breast Surgery, the 960th Hospital of the PLA Joint Logistics Support Force for providing necessary support. We are greatly indebted to Dr. Xiaolei Li for the initial collaboration and Dr. Fang Yu for providing suggestions for the submission of this manuscript.</p></ack><sec id="S0008"><title>Human and Animal Rights and Informed Consent</title><p>This article does not contain any studies with human or animal subjects performed by any of the authors.</p></sec><sec id="S0009"><title>Abbreviations</title><p>MT, matrine; OMT, oxymatrine; CKI, Compound Kushen Injection; TCM, Traditional Chinese Medicine; KS-As, Kushen alkaloids; KS-Fs, Kushen flavonoids; DSBs, double-strand breaks; CSCs, Breast cancer stem cells; IκB, inhibitor of κB; IKKs, IkB kinases; UPR, unfolded protein response; SG, sophoraflavanone G.</p></sec><sec id="S0010" sec-type="COI-statement"><title>Disclosure</title><p>The authors report no conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Chui</surname><given-names>CH</given-names></string-name>, <string-name><surname>Lau</surname><given-names>FY</given-names></string-name>, <string-name><surname>Tang</surname><given-names>JC</given-names></string-name>, et al. <article-title>Activities of fresh juice of Scutellaria barbata and warmed water extract of Radix Sophorae Tonkinensis on anti-proliferation and apoptosis of human cancer cell lines</article-title>. <source><italic toggle="yes">Int J Mol Med</italic></source>. <year>2005</year>;<volume>16</volume>:<fpage>337</fpage>–<lpage>341</lpage>.<pub-id pub-id-type="pmid">16012772</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Greenlee</surname><given-names>H</given-names></string-name>, <string-name><surname>DuPont-Reyes</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Balneaves</surname><given-names>LG</given-names></string-name>, et al. <article-title>Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment</article-title>. <source><italic toggle="yes">CA Cancer J Clin</italic></source>. <year>2017</year>;<volume>67</volume>:<fpage>194</fpage>–<lpage>232</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21397</pub-id><pub-id pub-id-type="pmid">28436999</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Liu</surname><given-names>X</given-names></string-name>, <string-name><surname>Chen</surname><given-names>H</given-names></string-name>, et al. <article-title>Multi-targeting chemoprevention of Chinese herb formula Yanghe Huayan decoction on experimentally induced mammary tumorigenesis</article-title>. <source><italic toggle="yes">BMC Complement Altern Med</italic></source>. <year>2019</year>;<volume>19</volume>:<fpage>48</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12906-019-2456-1</pub-id><pub-id pub-id-type="pmid">30760265</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Zhuang</surname><given-names>SR</given-names></string-name>, <string-name><surname>Chiu</surname><given-names>HF</given-names></string-name>, <string-name><surname>Chen</surname><given-names>SL</given-names></string-name>, et al. <article-title>Effects of a Chinese medical herbs complex on cellular immunity and toxicity-related conditions of breast cancer patients</article-title>. <source><italic toggle="yes">Br J Nutr</italic></source>. <year>2012</year>;<volume>107</volume>:<fpage>712</fpage>–<lpage>718</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S000711451100345X</pub-id><pub-id pub-id-type="pmid">21864416</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname><given-names>X</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Ge</surname><given-names>S</given-names></string-name>, et al. <article-title>Saikosaponin A inhibits breast cancer by regulating Th1/Th2 balance</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2019</year>;<volume>10</volume>:<fpage>624</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2019.00624</pub-id><pub-id pub-id-type="pmid">31214035</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Iwanowycz</surname><given-names>S</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Hodge</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yu</surname><given-names>F</given-names></string-name>, <string-name><surname>Fan</surname><given-names>D</given-names></string-name>. <article-title>Emodin inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages</article-title>. <source><italic toggle="yes">Mol Cancer Ther</italic></source>. <year>2016</year>;<volume>15</volume>:<fpage>1931</fpage>–<lpage>1942</lpage>. doi:<pub-id pub-id-type="doi">10.1158/1535-7163.MCT-15-0987</pub-id><pub-id pub-id-type="pmid">27196773</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Loo</surname><given-names>WT</given-names></string-name>, <string-name><surname>Wang</surname><given-names>N</given-names></string-name>, et al. <article-title>Effect of Sanguisorba officinalis L on breast cancer growth and angiogenesis</article-title>. <source><italic toggle="yes">Expert Opin Ther Targets</italic></source>. <year>2012</year>;<volume>16</volume>(<issue>Suppl 1</issue>):<fpage>S79</fpage>–<lpage>S89</lpage>. doi:<pub-id pub-id-type="doi">10.1517/14728222.2011.642371</pub-id><pub-id pub-id-type="pmid">22316502</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Wu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>D</given-names></string-name>, et al. <article-title>Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects</article-title>. <source><italic toggle="yes">Pharmacol Res</italic></source>. <year>2019</year>;<volume>146</volume>:<fpage>104313</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2019.104313</pub-id><pub-id pub-id-type="pmid">31202781</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname><given-names>L</given-names></string-name>, <string-name><surname>Li</surname><given-names>A</given-names></string-name>, <string-name><surname>Liao</surname><given-names>G</given-names></string-name>, et al. <article-title>Curcumol triggers apoptosis of p53 mutant triple-negative human breast cancer MDA-MB 231 cells via activation of p73 and PUMA</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2017</year>;<volume>14</volume>:<fpage>1080</fpage>–<lpage>1088</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2017.6273</pub-id><pub-id pub-id-type="pmid">28693277</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Patel</surname><given-names>A</given-names></string-name>, <string-name><surname>Soni</surname><given-names>A</given-names></string-name>, <string-name><surname>Siddiqi</surname><given-names>NJ</given-names></string-name>, <string-name><surname>Sharma</surname><given-names>P</given-names></string-name>. <article-title>An insight into the anticancer mechanism of Tribulus terrestris extracts on human breast cancer cells</article-title>. <source><italic toggle="yes">3 Biotech</italic></source>. <year>2019</year>;<volume>9</volume>:<fpage>58</fpage>. doi:<pub-id pub-id-type="doi">10.1007/s13205-019-1585-z</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Deng</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>F</given-names></string-name>, <string-name><surname>He</surname><given-names>P</given-names></string-name>, et al. <article-title>Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition</article-title>. <source><italic toggle="yes">Mol Carcinog</italic></source>. <year>2018</year>;<volume>57</volume>:<fpage>807</fpage>–<lpage>814</lpage>. doi:<pub-id pub-id-type="doi">10.1002/mc.v57.6</pub-id><pub-id pub-id-type="pmid">29500880</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Greenshields</surname><given-names>AL</given-names></string-name>, <string-name><surname>Fernando</surname><given-names>W</given-names></string-name>, <string-name><surname>Hoskin</surname><given-names>DW</given-names></string-name>. <article-title>The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells</article-title>. <source><italic toggle="yes">Exp Mol Pathol</italic></source>. <year>2019</year>;<volume>107</volume>:<fpage>10</fpage>–<lpage>22</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.yexmp.2019.01.006</pub-id><pub-id pub-id-type="pmid">30660598</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>von Hagens</surname><given-names>C</given-names></string-name>, <string-name><surname>Walter-Sack</surname><given-names>I</given-names></string-name>, <string-name><surname>Goeckenjan</surname><given-names>M</given-names></string-name>, et al. <article-title>Long-term add-on therapy (compassionate use) with oral artesunate in patients with metastatic breast cancer after participating in a phase I study (ARTIC M33/2)</article-title>. <source><italic toggle="yes">Phytomedicine</italic></source>. <year>2019</year>;<volume>54</volume>:<fpage>140</fpage>–<lpage>148</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phymed.2018.09.178</pub-id><pub-id pub-id-type="pmid">30668363</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <string-name><surname>Fan</surname><given-names>Y</given-names></string-name>, et al. <article-title>Anticancer efficiency of cycloartane triterpenoid derivatives isolated from Cimicifuga yunnanensis Hsiao on triple-negative breast cancer cells</article-title>. <source><italic toggle="yes">Cancer Manag Res</italic></source>. <year>2018</year>;<volume>10</volume>:<fpage>6715</fpage>–<lpage>6729</lpage>. doi:<pub-id pub-id-type="doi">10.2147/CMAR.S185387</pub-id><pub-id pub-id-type="pmid">30584366</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Dietz</surname><given-names>BM</given-names></string-name>, <string-name><surname>Hajirahimkhan</surname><given-names>A</given-names></string-name>, <string-name><surname>Dunlap</surname><given-names>TL</given-names></string-name>, <string-name><surname>Bolton</surname><given-names>JL</given-names></string-name>. <article-title>Botanicals and their bioactive phytochemicals for women’s health</article-title>. <source><italic toggle="yes">Pharmacol Rev</italic></source>. <year>2016</year>;<volume>68</volume>:<fpage>1026</fpage>–<lpage>1073</lpage>. doi:<pub-id pub-id-type="doi">10.1124/pr.115.010843</pub-id><pub-id pub-id-type="pmid">27677719</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>M</given-names></string-name>, <string-name><surname>Cao</surname><given-names>H</given-names></string-name>, <string-name><surname>Sun</surname><given-names>L</given-names></string-name>, et al. <article-title>Antitumor activities of Kushen: literature review</article-title>. <source><italic toggle="yes">Evid Based Complement Altern Med</italic></source>. <year>2012</year>;<volume>2012</volume>:<fpage>373219</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2012/373219</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Jin</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liang</surname><given-names>L</given-names></string-name>, et al. <article-title>Compound Kushen Injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2018</year>;<volume>37</volume>:<fpage>277</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13046-018-0948-3</pub-id><pub-id pub-id-type="pmid">30454068</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Tu</surname><given-names>H</given-names></string-name>, <string-name><surname>Lei</surname><given-names>B</given-names></string-name>, <string-name><surname>Meng</surname><given-names>S</given-names></string-name>, et al. <article-title>Efficacy of Compound Kushen Injection in combination with induction chemotherapy for treating adult patients newly diagnosed with acute leukemia</article-title>. <source><italic toggle="yes">Evid Based Complement Altern Med</italic></source>. <year>2016</year>;<volume>2016</volume>:<fpage>3121402</fpage>. doi:<pub-id pub-id-type="doi">10.1155/2016/3121402</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>J</given-names></string-name>, <string-name><surname>Qu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Yao</surname><given-names>H</given-names></string-name>, et al. <article-title>An effective drug sensitizing agent increases gefitinib treatment by down regulating PI3K/Akt/mTOR pathway and up regulating autophagy in non-small cell lung cancer</article-title>. <source><italic toggle="yes">Biomed Pharmacother</italic></source>. <year>2019</year>;<volume>118</volume>:<fpage>109169</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopha.2019.109169</pub-id><pub-id pub-id-type="pmid">31310954</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>XQ</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Lin</surname><given-names>HS</given-names></string-name>, <string-name><surname>Hou</surname><given-names>W</given-names></string-name>. <article-title>A multicenter randomized controlled open-label trial to assess the efficacy of Compound Kushen Injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomized controlled trial</article-title>. <source><italic toggle="yes">Trials</italic></source>. <year>2016</year>;<volume>17</volume>:<fpage>124</fpage>.<pub-id pub-id-type="pmid">26956875</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Gao</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>KX</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>YZ</given-names></string-name>, <string-name><surname>Fang</surname><given-names>JS</given-names></string-name>, <string-name><surname>Qin</surname><given-names>XM</given-names></string-name>, <string-name><surname>Du</surname><given-names>GH</given-names></string-name>. <article-title>Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2018</year>;<volume>8</volume>:<fpage>624</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-017-18325-7</pub-id><pub-id pub-id-type="pmid">29330507</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Nourmohammadi</surname><given-names>S</given-names></string-name>, <string-name><surname>Aung</surname><given-names>TN</given-names></string-name>, <string-name><surname>Cui</surname><given-names>J</given-names></string-name>, et al. <article-title>Effect of Compound Kushen Injection, a natural compound mixture, and its identified chemical components on migration and invasion of colon, brain, and breast cancer cell lines</article-title>. <source><italic toggle="yes">Front Oncol</italic></source>. <year>2019</year>;<volume>9</volume>:<fpage>314</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fonc.2019.00314</pub-id><pub-id pub-id-type="pmid">31106149</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Qu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Cui</surname><given-names>J</given-names></string-name>, <string-name><surname>Harata-Lee</surname><given-names>Y</given-names></string-name>, et al. <article-title>Identification of candidate anti-cancer molecular mechanisms of Compound Kushen Injection using functional genomics</article-title>. <source><italic toggle="yes">Oncotarget</italic></source>. <year>2016</year>;<volume>7</volume>:<fpage>66003</fpage>–<lpage>66019</lpage>. doi:<pub-id pub-id-type="doi">10.18632/oncotarget.v7i40</pub-id><pub-id pub-id-type="pmid">27602759</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Cui</surname><given-names>J</given-names></string-name>, <string-name><surname>Qu</surname><given-names>Z</given-names></string-name>, <string-name><surname>Harata-Lee</surname><given-names>Y</given-names></string-name>, et al. <article-title>Cell cycle, energy metabolism and DNA repair pathways in cancer cells are suppressed by Compound Kushen Injection</article-title>. <source><italic toggle="yes">BMC Cancer</italic></source>. <year>2019</year>;<volume>19</volume>:<fpage>103</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12885-018-5230-8</pub-id><pub-id pub-id-type="pmid">30678652</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name><surname>Lin</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Compound Kushen Injection suppresses human breast cancer stem-like cells by down-regulating the canonical Wnt/beta-catenin pathway</article-title>. <source><italic toggle="yes">J Exp Clin Cancer Res</italic></source>. <year>2011</year>;<volume>30</volume>:<fpage>103</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1756-9966-30-103</pub-id><pub-id pub-id-type="pmid">22032476</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>H</given-names></string-name>, <string-name><surname>Hu</surname><given-names>H</given-names></string-name>, <string-name><surname>Rong</surname><given-names>H</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>X</given-names></string-name>. <article-title>Effects of Compound Kushen Injection on pathology and angiogenesis of tumor tissues</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2019</year>;<volume>17</volume>:<fpage>2278</fpage>–<lpage>2282</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2018.9861</pub-id><pub-id pub-id-type="pmid">30719109</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>HY</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>He</surname><given-names>QY</given-names></string-name>. <article-title>Mechanisms of yanshu injection for overcoming multidrug resistance in breast carcinoma MCF-7 cells: an experimental research</article-title>. <source><italic toggle="yes">Chin J Integr Med</italic></source>. <year>2014</year>;<volume>34</volume>:<fpage>324</fpage>–<lpage>328</lpage>.</mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Long</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zeng</surname><given-names>ZT</given-names></string-name>, <string-name><surname>Li</surname><given-names>YC</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>. <article-title>Effect of compound matrine injection in the model rats of breast cancer</article-title>. <source><italic toggle="yes">Chin J Clin Pharmacol</italic></source>. <year>2018</year>;<volume>34</volume>:<fpage>141</fpage>–<lpage>144</lpage>.</mixed-citation></ref><ref id="CIT0029"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Lai</surname><given-names>MH</given-names></string-name>. <article-title>Improvement of compound matrine injection in breast cancer model rat</article-title>. <source><italic toggle="yes">Chin J Clin Pharmacol</italic></source>. <year>2017</year>;<volume>33</volume>:<fpage>244</fpage>–<lpage>247</lpage>.</mixed-citation></ref><ref id="CIT0030"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Hou</surname><given-names>G</given-names></string-name>, <string-name><surname>Li</surname><given-names>N</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>YP</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>CH</given-names></string-name>, <string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Liu</surname><given-names>ZW</given-names></string-name>. <article-title>Expression of Survivin in breast cancer and study on the effectiveness of matrine</article-title>. <source><italic toggle="yes">Mod Oncol</italic></source>. <year>2018</year>;<volume>26</volume>:<fpage>388</fpage>–<lpage>391</lpage>.</mixed-citation></ref><ref id="CIT0031"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Wen</surname><given-names>B</given-names></string-name>, <string-name><surname>Yang</surname><given-names>ZH</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>WT</given-names></string-name>. <article-title>Clinical significance of changes of serum VEGF-A in breast cancer patients with combination with radiotherapy and matrine</article-title>. <source><italic toggle="yes">Chin J Lab Diagn</italic></source>. <year>2011</year>;<volume>15</volume>:<fpage>1916</fpage>–<lpage>1917</lpage>.</mixed-citation></ref><ref id="CIT0032"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Fu</surname><given-names>FM</given-names></string-name>, <string-name><surname>Luo</surname><given-names>SH</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Meta-analysis the effect of Fufangkushen injection combined with chemotherapy on immune function in patients with breast cancer</article-title>. <source><italic toggle="yes">Pract Clin J Integr Tradit Chin West Med</italic></source>. <year>2018</year>;<volume>18</volume>:<page-range>1-4+22</page-range>.</mixed-citation></ref><ref id="CIT0033"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Gu</surname><given-names>XD</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>H</given-names></string-name>, <string-name><surname>Xie</surname><given-names>XH</given-names></string-name>. <article-title>Effect of Compound Kushen Injection combined with neoadjuvant chemotherapy for locally advanced breast cancer</article-title>. <source><italic toggle="yes">Zhejiang J Tradit Chin Med</italic></source>. <year>2015</year>;<volume>50</volume>:<fpage>74</fpage>.</mixed-citation></ref><ref id="CIT0034"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Zhai</surname><given-names>XJ</given-names></string-name>. <article-title>Effects of Compound Kushen Injection on immune function and toxicity reaction of patients with postoperative chemotherapy for breast cancer</article-title>. <source><italic toggle="yes">Chin J Basic Medi Tradit Chin Med</italic></source>. <year>2014</year>;<volume>20</volume>:<fpage>829</fpage>–<lpage>831</lpage>.</mixed-citation></ref><ref id="CIT0035"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname><given-names>PF</given-names></string-name>, <string-name><surname>Chen</surname><given-names>MX</given-names></string-name>, <string-name><surname>Yang</surname><given-names>YY</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>YM</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>HC</given-names></string-name>. <article-title>Clinical effect of postoperative radiotherapy combined with compound matrine injection on the patients with breast cancer</article-title>. <source><italic toggle="yes">Prog Mod Biomed</italic></source>. <year>2017</year>;<volume>17</volume>:<page-range>5255-7+66</page-range>.</mixed-citation></ref><ref id="CIT0036"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Maimaitiniyazi</surname><given-names>S</given-names></string-name>, <string-name><surname>Ai</surname><given-names>XQ</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>XL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>YH</given-names></string-name>, <string-name><surname>Mushajiang</surname><given-names>M</given-names></string-name>. <article-title>Effects of compound Kushen Injection combined with postoperative radiotherapy on immune function and quality of life for breast cancer</article-title>. <source><italic toggle="yes">Hainan MED J</italic></source>. <year>2016</year>;<volume>27</volume>:<fpage>2283</fpage>–<lpage>2285</lpage>.</mixed-citation></ref><ref id="CIT0037"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Yasheng</surname><given-names>A</given-names></string-name>, <string-name><surname>Ai</surname><given-names>XY</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>JZN</given-names></string-name>, <string-name><surname>Tong</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>B</given-names></string-name>. <article-title>Toxic and side effects of compound matrine injection in breast cancer adjuvant chemotherapy</article-title>. <source><italic toggle="yes">Liaoning J Tradit Chin Med</italic></source>. <year>2016</year>;<volume>43</volume>:<fpage>2101</fpage>–<lpage>2102</lpage>.</mixed-citation></ref><ref id="CIT0038"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>LJ</given-names></string-name>. <article-title>Efficacy analysis of Compound Kushen Injection as adjunctive treatment for breast cancer</article-title>. <source><italic toggle="yes">China Pharm</italic></source>. <year>2010</year>;<volume>21</volume>:<fpage>1866</fpage>–<lpage>1867</lpage>.</mixed-citation></ref><ref id="CIT0039"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>An</surname><given-names>AJ</given-names></string-name>, <string-name><surname>An</surname><given-names>GW</given-names></string-name>, <string-name><surname>Wu</surname><given-names>YC</given-names></string-name>. <article-title>Observation of compound recipe light yellow sophora root injecta combined with chemotherapy in treatment of 35 postoperative patients with breast cancer</article-title>. <source><italic toggle="yes">Med Pharm J Chin PLA</italic></source>. <year>2012</year>;<volume>24</volume>:<fpage>43</fpage>–<lpage>46</lpage>.</mixed-citation></ref><ref id="CIT0040"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>YX</given-names></string-name>. <article-title>Clinical observation of Compound Kusheng Injection combined with chemotherapy in treatment of three negative breast cancer</article-title>. <source><italic toggle="yes">World Latest Med Inf</italic></source>. <year>2018</year>;<volume>18</volume>:<fpage>3</fpage>–<lpage>4</lpage>.</mixed-citation></ref><ref id="CIT0041"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Gao</surname><given-names>QF</given-names></string-name>. <article-title>Clinical observation of Compound Kusheng Injection combined with postoperative chemotherapy for breast cancer</article-title>. <source><italic toggle="yes">Liaoning J Tradit Chin Med</italic></source>. <year>2015</year>;<volume>42</volume>:<fpage>1928</fpage>–<lpage>1929</lpage>.</mixed-citation></ref><ref id="CIT0042"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Bai</surname><given-names>ZQ</given-names></string-name>. <article-title>63 cases of clinical observation research of zoleronic acid injection joint compound sophora injection on the treatment for breast cancer bone metastasis</article-title>. <source><italic toggle="yes">Chin J Hosp Pharm</italic></source>. <year>2016</year>;<volume>36</volume>:<fpage>328</fpage>–<lpage>329</lpage>.</mixed-citation></ref><ref id="CIT0043"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Hu</surname><given-names>G</given-names></string-name>, <string-name><surname>Dong</surname><given-names>Y</given-names></string-name>, et al. <article-title>Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells</article-title>. <source><italic toggle="yes">J Cell Mol Med</italic></source>. <year>2017</year>;<volume>21</volume>:<fpage>1171</fpage>–<lpage>1181</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jcmm.2017.21.issue-6</pub-id><pub-id pub-id-type="pmid">28026112</pub-id></mixed-citation></ref><ref id="CIT0044"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Xie</surname><given-names>M</given-names></string-name>, <string-name><surname>He</surname><given-names>G</given-names></string-name>, <string-name><surname>Wang</surname><given-names>R</given-names></string-name>, et al. <article-title>Matrine-induced apoptosis of human nasopharyngeal carcinoma cells via in vitro vascular endothelial growth factor-A/extracellular signal-regulated kinase1/2 pathway inactivation</article-title>. <source><italic toggle="yes">Hormone Metab Res</italic></source>. <year>2014</year>;<volume>46</volume>:<fpage>556</fpage>–<lpage>560</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-00000025</pub-id></mixed-citation></ref><ref id="CIT0045"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Qian</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname><given-names>Y</given-names></string-name>, et al. <article-title>Matrine derivative WM130 inhibits hepatocellular carcinoma by suppressing EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways</article-title>. <source><italic toggle="yes">Cancer Lett</italic></source>. <year>2015</year>;<volume>368</volume>:<fpage>126</fpage>–<lpage>134</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2015.07.035</pub-id><pub-id pub-id-type="pmid">26259512</pub-id></mixed-citation></ref><ref id="CIT0046"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name><surname>Xu</surname><given-names>M</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Y</given-names></string-name>, et al. <article-title>Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor</article-title>. <source><italic toggle="yes">Mol Cancer</italic></source>. <year>2014</year>;<volume>13</volume>:<fpage>59</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1476-4598-13-59</pub-id><pub-id pub-id-type="pmid">24628719</pub-id></mixed-citation></ref><ref id="CIT0047"><label>47.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Fang</surname><given-names>B</given-names></string-name>, <string-name><surname>Yao</surname><given-names>J</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B</given-names></string-name>. <article-title>Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial mesenchymal transition</article-title>. <source><italic toggle="yes">Mol Med Rep</italic></source>. <year>2018</year>;<volume>18</volume>:<fpage>911</fpage>–<lpage>919</lpage>. doi:<pub-id pub-id-type="doi">10.3892/mmr.2018.9023</pub-id><pub-id pub-id-type="pmid">29845189</pub-id></mixed-citation></ref><ref id="CIT0048"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name><surname>Cai</surname><given-names>D</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>. <article-title>Matrine inhibits the metastatic properties of human cervical cancer cells via downregulating the p38 signaling pathway</article-title>. <source><italic toggle="yes">Oncol Rep</italic></source>. <year>2017</year>;<volume>38</volume>:<fpage>1312</fpage>–<lpage>1320</lpage>. doi:<pub-id pub-id-type="doi">10.3892/or.2017.5787</pub-id><pub-id pub-id-type="pmid">28677790</pub-id></mixed-citation></ref><ref id="CIT0049"><label>49.</label><mixed-citation publication-type="journal"><string-name><surname>Gu</surname><given-names>YY</given-names></string-name>, <string-name><surname>Chen</surname><given-names>MH</given-names></string-name>, <string-name><surname>May</surname><given-names>BH</given-names></string-name>, et al. <article-title>Matrine induces apoptosis in multiple colorectal cancer cell lines in vitro and inhibits tumour growth with minimum side effects in vivo via Bcl-2 and caspase-3</article-title>. <source><italic toggle="yes">Phytomedicine</italic></source>. <year>2018</year>;<volume>51</volume>:<fpage>214</fpage>–<lpage>225</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phymed.2018.10.004</pub-id><pub-id pub-id-type="pmid">30466620</pub-id></mixed-citation></ref><ref id="CIT0050"><label>50.</label><mixed-citation publication-type="journal"><string-name><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Guo</surname><given-names>JX</given-names></string-name>, <string-name><surname>Shao</surname><given-names>ZQ</given-names></string-name>, <string-name><surname>Gao</surname><given-names>JP</given-names></string-name>. <article-title>Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: an experimental study</article-title>. <source><italic toggle="yes">Asian Pac J Trop Med</italic></source>. <year>2017</year>;<volume>10</volume>:<fpage>515</fpage>–<lpage>519</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apjtm.2017.05.009</pub-id><pub-id pub-id-type="pmid">28647190</pub-id></mixed-citation></ref><ref id="CIT0051"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Chong</surname><given-names>T</given-names></string-name>, <string-name><surname>Ji</surname><given-names>Z</given-names></string-name>. <article-title>Matrine inhibits proliferation and induces apoptosis of the androgen independent prostate cancer cell line PC-3</article-title>. <source><italic toggle="yes">Mol Med Rep</italic></source>. <year>2012</year>;<volume>5</volume>:<fpage>783</fpage>–<lpage>787</lpage>. doi:<pub-id pub-id-type="doi">10.3892/mmr.2011.701</pub-id><pub-id pub-id-type="pmid">22159447</pub-id></mixed-citation></ref><ref id="CIT0052"><label>52.</label><mixed-citation publication-type="journal"><string-name><surname>Huang</surname><given-names>H</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Du</surname><given-names>T</given-names></string-name>, et al. <article-title>Matrine inhibits the progression of prostate cancer by promoting expression of GADD45B</article-title>. <source><italic toggle="yes">Prostate</italic></source>. <year>2018</year>;<volume>78</volume>:<fpage>327</fpage>–<lpage>335</lpage>. doi:<pub-id pub-id-type="doi">10.1002/pros.v78.5</pub-id><pub-id pub-id-type="pmid">29356020</pub-id></mixed-citation></ref><ref id="CIT0053"><label>53.</label><mixed-citation publication-type="journal"><string-name><surname>Xie</surname><given-names>W</given-names></string-name>, <string-name><surname>Lu</surname><given-names>J</given-names></string-name>, <string-name><surname>Lu</surname><given-names>Q</given-names></string-name>, et al. <article-title>Matrine inhibits the proliferation and migration of lung cancer cells through regulation of the protein kinase B/glycogen synthase kinase-3beta signaling pathways</article-title>. <source><italic toggle="yes">Exp Ther Med</italic></source>. <year>2018</year>;<volume>16</volume>:<fpage>723</fpage>–<lpage>729</lpage>. doi:<pub-id pub-id-type="doi">10.3892/etm.2018.6266</pub-id><pub-id pub-id-type="pmid">30112033</pub-id></mixed-citation></ref><ref id="CIT0054"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Cho</surname><given-names>YR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>JH</given-names></string-name>, et al. <article-title>Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism</article-title>. <source><italic toggle="yes">Mol Oncol</italic></source>. <year>2018</year>;<volume>12</volume>:<fpage>1203</fpage>–<lpage>1215</lpage>. doi:<pub-id pub-id-type="doi">10.1002/1878-0261.12324</pub-id><pub-id pub-id-type="pmid">29791786</pub-id></mixed-citation></ref><ref id="CIT0055"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>D</given-names></string-name>, <string-name><surname>Cao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>L</given-names></string-name>, et al. <article-title>Identification of Annexin A2 as a target protein for plant alkaloid matrine</article-title>. <source><italic toggle="yes">Chem Commun</italic></source>. <year>2017</year>;<volume>53</volume>:<fpage>5020</fpage>–<lpage>5023</lpage>. doi:<pub-id pub-id-type="doi">10.1039/C7CC02227A</pub-id></mixed-citation></ref><ref id="CIT0056"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Feng</surname><given-names>Q</given-names></string-name>, <string-name><surname>Yang</surname><given-names>X</given-names></string-name>, <string-name><surname>Hao</surname><given-names>Y</given-names></string-name>, et al. <article-title>Cancer cell membrane-biomimetic nanoplatform for enhanced sonodynamic therapy on breast cancer via autophagy regulation strategy</article-title>. <source><italic toggle="yes">ACS Appl Mater Interfaces</italic></source>. <year>2019</year>;<volume>11</volume>:<fpage>32729</fpage>–<lpage>32738</lpage>. doi:<pub-id pub-id-type="doi">10.1021/acsami.9b10948</pub-id><pub-id pub-id-type="pmid">31415145</pub-id></mixed-citation></ref><ref id="CIT0057"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Ren</surname><given-names>LL</given-names></string-name>, <string-name><surname>Lan</surname><given-names>T</given-names></string-name>, <string-name><surname>Wang</surname><given-names>XJ</given-names></string-name>. <article-title>Antitumor effect of matrine in human breast cancer Bcap-37 cells by apoptosis and autophagy</article-title>. <source><italic toggle="yes">Chin Archiv Tradit Chin Med</italic></source>. <year>2014</year>;<volume>32</volume>:<fpage>2756</fpage>–<lpage>2759</lpage>.</mixed-citation></ref><ref id="CIT0058"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Ren</surname><given-names>LL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>LL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>XJ</given-names></string-name>. <article-title>Relationship between matrine induced autophagy and mTOR in human breast cancer Bcap-37 cells</article-title>. <source><italic toggle="yes">Zhejiang JITCWM</italic></source>. <year>2016</year>;<volume>26</volume>:<fpage>783</fpage>–<lpage>786</lpage>.</mixed-citation></ref><ref id="CIT0059"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>BG</given-names></string-name>, <string-name><surname>Sun</surname><given-names>JZ</given-names></string-name>, <string-name><surname>Su</surname><given-names>G</given-names></string-name>, <string-name><surname>Ma</surname><given-names>DQ</given-names></string-name>. <article-title>Apoptosis of human breast cancer MCF-7/ADR cells induced by matrine</article-title>. <source><italic toggle="yes">Chin J Exp Surg</italic></source>. <year>2003</year>;<volume>20</volume>:<fpage>515</fpage>–<lpage>516</lpage>.</mixed-citation></ref><ref id="CIT0060"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>P</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Q</given-names></string-name>, <string-name><surname>Liu</surname><given-names>K</given-names></string-name>, <string-name><surname>Yagasaki</surname><given-names>K</given-names></string-name>, <string-name><surname>Wu</surname><given-names>E</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>. <article-title>Matrine suppresses breast cancer cell proliferation and invasion via VEGF-Akt-NF-kappaB signaling</article-title>. <source><italic toggle="yes">Cytotechnology</italic></source>. <year>2009</year>;<volume>59</volume>:<fpage>219</fpage>–<lpage>229</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10616-009-9225-9</pub-id><pub-id pub-id-type="pmid">19760125</pub-id></mixed-citation></ref><ref id="CIT0061"><label>61.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Tan</surname><given-names>G</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>X</given-names></string-name>, et al. <article-title>Therapeutic effects of matrine on primary and metastatic breast cancer</article-title>. <source><italic toggle="yes">Am J Chin Med (Gard City N Y)</italic></source>. <year>2010</year>;<volume>38</volume>:<fpage>1115</fpage>–<lpage>1130</lpage>. doi:<pub-id pub-id-type="doi">10.1142/S0192415X10008512</pub-id></mixed-citation></ref><ref id="CIT0062"><label>62.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>JY</given-names></string-name>, <string-name><surname>Shao</surname><given-names>XY</given-names></string-name>, <string-name><surname>Wang</surname><given-names>XJ</given-names></string-name>. <article-title>Mechanism of matrine promoting apoptosis induced by tamoxifen in breast cancer cell Bcap-37</article-title>. <source><italic toggle="yes">J Chin Oncol</italic></source>. <year>2012</year>;<volume>18</volume>:<fpage>840</fpage>–<lpage>843</lpage>.</mixed-citation></ref><ref id="CIT0063"><label>63.</label><mixed-citation publication-type="journal"><string-name><surname>Zheng</surname><given-names>RZ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>JY</given-names></string-name>, <string-name><surname>Shao</surname><given-names>XY</given-names></string-name>, <string-name><surname>Wang</surname><given-names>XJ</given-names></string-name>. <article-title>Inhibition of the growth of human breast cancer cell line Bcap-37 with matrine</article-title>. <source><italic toggle="yes">Zhejiang JITCWM</italic></source>. <year>2012</year>;<volume>22</volume>:<fpage>945</fpage>–<lpage>947</lpage>.</mixed-citation></ref><ref id="CIT0064"><label>64.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>XX</given-names></string-name>, <string-name><surname>Bai</surname><given-names>ML</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>LX</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name>, <string-name><surname>Ge</surname><given-names>LP</given-names></string-name>. <article-title>Effects of matrine on proliferation and apoptosis in human breast cancer MCF-7 cells</article-title>. <source><italic toggle="yes">Jiangsu Med J</italic></source>. <year>2011</year>;<volume>37</volume>:<page-range>396-8+68</page-range>.</mixed-citation></ref><ref id="CIT0065"><label>65.</label><mixed-citation publication-type="journal"><string-name><surname>Xiao</surname><given-names>X</given-names></string-name>, <string-name><surname>Ao</surname><given-names>M</given-names></string-name>, <string-name><surname>Shi</surname><given-names>WD</given-names></string-name>, et al. <article-title>The effect of matrine on proliferation and apoptosis in breast cancer MCF-7 cells</article-title>. <source><italic toggle="yes">Chin Tradit Patent Med</italic></source>. <year>2018</year>;<volume>40</volume>:<fpage>2750</fpage>–<lpage>2754</lpage>.</mixed-citation></ref><ref id="CIT0066"><label>66.</label><mixed-citation publication-type="journal"><string-name><surname>Sui</surname><given-names>H</given-names></string-name>. <article-title>Effects of matrine on proliferation of human breast cancer cells</article-title>. <source><italic toggle="yes">China J Mod Med</italic></source>. <year>2013</year>;<volume>23</volume>:<fpage>41</fpage>–<lpage>43</lpage>.</mixed-citation></ref><ref id="CIT0067"><label>67.</label><mixed-citation publication-type="journal"><string-name><surname>Wang</surname><given-names>SQ</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XL</given-names></string-name>, <string-name><surname>Li</surname><given-names>YZ</given-names></string-name>, <string-name><surname>Hao</surname><given-names>XQ</given-names></string-name>. <article-title>Matrine induces apoptosis in MCF-7 breast cancer cells and it’s effect on Bax</article-title>. <source><italic toggle="yes">Chin J Gerontol</italic></source>. <year>2012</year>;<volume>32</volume>:<fpage>3489</fpage>–<lpage>3491</lpage>.</mixed-citation></ref><ref id="CIT0068"><label>68.</label><mixed-citation publication-type="journal"><string-name><surname>Zhao</surname><given-names>WG</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhuang</surname><given-names>J</given-names></string-name>, <string-name><surname>Feng</surname><given-names>FB</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Sun</surname><given-names>CG</given-names></string-name>. <article-title>Matrine with adriamycin has synergistic effect on human breast cancer cells</article-title>. <source><italic toggle="yes">Lishizhen Med Mater Med Res</italic></source>. <year>2018</year>;<volume>29</volume>:<fpage>33</fpage>–<lpage>36</lpage>.</mixed-citation></ref><ref id="CIT0069"><label>69.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>BG</given-names></string-name>, <string-name><surname>Wei</surname><given-names>CS</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Gao</surname><given-names>HM</given-names></string-name>. <article-title>Matrine reversed multidrug resistance of breast cancer MCF-7/ADR cells through PI3K/AKT signaling pathway</article-title>. <source><italic toggle="yes">J Cell Biochem</italic></source>. <year>2018</year>;<volume>119</volume>:<fpage>3885</fpage>–<lpage>3891</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcb.26502</pub-id><pub-id pub-id-type="pmid">29130495</pub-id></mixed-citation></ref><ref id="CIT0070"><label>70.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Bai</surname><given-names>M</given-names></string-name>, <string-name><surname>Suo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>G</given-names></string-name>, <string-name><surname>Cao</surname><given-names>X</given-names></string-name>. <article-title>Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2</article-title>. <source><italic toggle="yes">Int J Clin Exp Pathol</italic></source>. <year>2015</year>;<volume>8</volume>:<fpage>14793</fpage>–<lpage>14799</lpage>.<pub-id pub-id-type="pmid">26823806</pub-id></mixed-citation></ref><ref id="CIT0071"><label>71.</label><mixed-citation publication-type="journal"><string-name><surname>Xiao</surname><given-names>X</given-names></string-name>, <string-name><surname>Ao</surname><given-names>M</given-names></string-name>, <string-name><surname>Xu</surname><given-names>F</given-names></string-name>, et al. <article-title>Effect of matrine against breast cancer by downregulating the vascular endothelial growth factor via the Wnt/beta-catenin pathway</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2018</year>;<volume>15</volume>:<fpage>1691</fpage>–<lpage>1697</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2017.7519</pub-id><pub-id pub-id-type="pmid">29434864</pub-id></mixed-citation></ref><ref id="CIT0072"><label>72.</label><mixed-citation publication-type="journal"><string-name><surname>Shao</surname><given-names>H</given-names></string-name>, <string-name><surname>Yang</surname><given-names>B</given-names></string-name>, <string-name><surname>Hu</surname><given-names>R</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>. <article-title>Matrine effectively inhibits the proliferation of breast cancer cells through a mechanism related to the NF-kappaB signaling pathway</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2013</year>;<volume>6</volume>:<fpage>517</fpage>–<lpage>520</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2013.1399</pub-id><pub-id pub-id-type="pmid">24137358</pub-id></mixed-citation></ref><ref id="CIT0073"><label>73.</label><mixed-citation publication-type="journal"><string-name><surname>Xiao</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ma</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>H</given-names></string-name>, et al. <article-title>Matrine suppresses the ER-positive MCF cells by regulating energy metabolism and endoplasmic reticulum stress signaling pathway</article-title>. <source><italic toggle="yes">Phytother Res</italic></source>. <year>2017</year>;<volume>31</volume>:<fpage>671</fpage>–<lpage>679</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ptr.v31.4</pub-id><pub-id pub-id-type="pmid">28185329</pub-id></mixed-citation></ref><ref id="CIT0074"><label>74.</label><mixed-citation publication-type="journal"><string-name><surname>Gu</surname><given-names>MR</given-names></string-name>, <string-name><surname>Li</surname><given-names>JB</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>XH</given-names></string-name>, <string-name><surname>Yin</surname><given-names>YM</given-names></string-name>. <article-title>Analysis of induced apoptosis effect of matrine on human breast cancer MCF-7 cell and its effect on mitochondrial transmembrane potential</article-title>. <source><italic toggle="yes">Chin J Biochem Pharm</italic></source>. <year>2015</year>;<volume>35</volume>:<fpage>39</fpage>–<lpage>41</lpage>.</mixed-citation></ref><ref id="CIT0075"><label>75.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>XX</given-names></string-name>, <string-name><surname>Bai</surname><given-names>ML</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>LX</given-names></string-name>, <string-name><surname>Li</surname><given-names>YZ</given-names></string-name>, <string-name><surname>Liu</surname><given-names>H</given-names></string-name>. <article-title>The effect of matrine on apoptosis and mitochondrial transmembrane potential in MCF-7 cells</article-title>. <source><italic toggle="yes">Lishizhen Med Mater Med Res</italic></source>. <year>2011</year>;<volume>22</volume>:<fpage>2042</fpage>–<lpage>2043</lpage>.</mixed-citation></ref><ref id="CIT0076"><label>76.</label><mixed-citation publication-type="journal"><string-name><surname>Shi</surname><given-names>WD</given-names></string-name>, <string-name><surname>Li</surname><given-names>DX</given-names></string-name>, <string-name><surname>Hu</surname><given-names>JL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>N</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>X</given-names></string-name>. <article-title>Matrine inhibits proliferation of breast cancer 4T1 cells by regulating expression of annexin A3</article-title>. <source><italic toggle="yes">Ningxia Med J</italic></source>. <year>2019</year>;<volume>9</volume>:<fpage>967</fpage>–<lpage>969</lpage>.</mixed-citation></ref><ref id="CIT0077"><label>77.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>LQ</given-names></string-name>, <string-name><surname>Li</surname><given-names>XL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>L</given-names></string-name>, et al. <article-title>Matrine inhibits breast cancer growth via miR-21/PTEN/Akt pathway in MCF-7 cells</article-title>. <source><italic toggle="yes">Cell Physiol Biochem</italic></source>. <year>2012</year>;<volume>30</volume>:<fpage>631</fpage>–<lpage>641</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000341444</pub-id><pub-id pub-id-type="pmid">22832383</pub-id></mixed-citation></ref><ref id="CIT0078"><label>78.</label><mixed-citation publication-type="journal"><string-name><surname>Xiao</surname><given-names>X</given-names></string-name>, <string-name><surname>Man</surname><given-names>A</given-names></string-name>, <string-name><surname>Shi</surname><given-names>WD</given-names></string-name>, et al. <article-title>Effects of matrine on proliferation and apoptosis of breast cancer SK-BR-3 cells</article-title>. <source><italic toggle="yes">Shandong Med J</italic></source>. <year>2018</year>;<volume>58</volume>:<fpage>24</fpage>–<lpage>27</lpage>.</mixed-citation></ref><ref id="CIT0079"><label>79.</label><mixed-citation publication-type="journal"><string-name><surname>Yu</surname><given-names>M</given-names></string-name>, <string-name><surname>Cao</surname><given-names>F</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>R</given-names></string-name>, <string-name><surname>Ding</surname><given-names>HZ</given-names></string-name>. <article-title>Effect of ZIC1 associated with matrine on proliferation, migration and apoptosis in MDAMB-231 human breast cancer cell line</article-title>. <source><italic toggle="yes">Mod Oncol</italic></source>. <year>2016</year>;<volume>24</volume>:<fpage>1528</fpage>–<lpage>1533</lpage>.</mixed-citation></ref><ref id="CIT0080"><label>80.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>BG</given-names></string-name>, <string-name><surname>Wei</surname><given-names>CS</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>. <article-title>The matrine reverse multidrug resistance on breast cancer MCF-7/ADR cell line and have an influence on downstream factors of PI3K/AKT signal pathway</article-title>. <source><italic toggle="yes">Mod Oncol</italic></source>. <year>2017</year>;<volume>25</volume>:<fpage>9</fpage>–<lpage>13</lpage>.</mixed-citation></ref><ref id="CIT0081"><label>81.</label><mixed-citation publication-type="journal"><string-name><surname>Wei</surname><given-names>CS</given-names></string-name>, <string-name><surname>Shen</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Z</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>BG</given-names></string-name>. <article-title>Matrine reverses multidrug resistance in breast cancer drug-resistant cell line MCF-7/ADR through inhibiting PI3K/AKT signal pathway</article-title>. <source><italic toggle="yes">J Third Mil Med Univ</italic></source>. <year>2014</year>;<volume>36</volume>:<fpage>2254</fpage>–<lpage>2258</lpage>.</mixed-citation></ref><ref id="CIT0082"><label>82.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>HY</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Y</given-names></string-name>, <string-name><surname>He</surname><given-names>QY</given-names></string-name>. <article-title>Mechanism of combination of matrine and tetrandrine for reversal of multidrug resistance of breast carcinoma MCF-7 cells</article-title>. <source><italic toggle="yes">Chin J Exp Tradit Med Formulae</italic></source>. <year>2013</year>;<volume>19</volume>:<fpage>275</fpage>–<lpage>278</lpage>.</mixed-citation></ref><ref id="CIT0083"><label>83.</label><mixed-citation publication-type="journal"><string-name><surname>Lao</surname><given-names>YQ</given-names></string-name>. <article-title>Effect of matrine injection on preventing liver function damage for breast cancer with chemotherapy</article-title>. <source><italic toggle="yes">J Chin Med Mater</italic></source>. <year>2005</year>;<volume>28</volume>:<fpage>735</fpage>–<lpage>737</lpage>.</mixed-citation></ref><ref id="CIT0084"><label>84.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Guo</surname><given-names>YJ</given-names></string-name>, <string-name><surname>Yang</surname><given-names>XL</given-names></string-name>, <string-name><surname>Ou</surname><given-names>ZL</given-names></string-name>. <article-title>Anti-cervical cancer role of matrine, oxymatrine and sophora flavescens alkaloid gels and its mechanism</article-title>. <source><italic toggle="yes">J Cancer</italic></source>. <year>2018</year>;<volume>9</volume>:<fpage>1357</fpage>–<lpage>1364</lpage>. doi:<pub-id pub-id-type="doi">10.7150/jca.22427</pub-id><pub-id pub-id-type="pmid">29721044</pub-id></mixed-citation></ref><ref id="CIT0085"><label>85.</label><mixed-citation publication-type="journal"><string-name><surname>Halim</surname><given-names>CE</given-names></string-name>, <string-name><surname>Xinjing</surname><given-names>SL</given-names></string-name>, <string-name><surname>Fan</surname><given-names>L</given-names></string-name>, et al. <article-title>Anti-cancer effects of oxymatrine are mediated through multiple molecular mechanism(s) in tumor models</article-title>. <source><italic toggle="yes">Pharmacol Res</italic></source>. <year>2019</year>;<volume>147</volume>:<fpage>104327</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2019.104327</pub-id><pub-id pub-id-type="pmid">31283981</pub-id></mixed-citation></ref><ref id="CIT0086"><label>86.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname><given-names>G</given-names></string-name>, <string-name><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name><surname>Fan</surname><given-names>YZ</given-names></string-name>, <string-name><surname>Su</surname><given-names>G</given-names></string-name>. <article-title>Oxymatrine induces Apoptosis in MCF-7 breast cancer cells</article-title>. <source><italic toggle="yes">Chin Pharmacol Bull</italic></source>. <year>2002</year>;<volume>11</volume>:<fpage>689</fpage>–<lpage>691</lpage>.</mixed-citation></ref><ref id="CIT0087"><label>87.</label><mixed-citation publication-type="journal"><string-name><surname>Cai</surname><given-names>JQ</given-names></string-name>, <string-name><surname>Wei</surname><given-names>XX</given-names></string-name>, <string-name><surname>Huang</surname><given-names>XX</given-names></string-name>, <string-name><surname>Zhuang</surname><given-names>J</given-names></string-name>, <string-name><surname>Sun</surname><given-names>H</given-names></string-name>. <article-title>Oxymatrine inhibits invasion and metastasis of human breast cancer cells in vitro through regulating epithelial-mesenchymal transition</article-title>. <source><italic toggle="yes">Chin J Clin Pharmacol Ther</italic></source>. <year>2018</year>;<volume>23</volume>:<fpage>13</fpage>–<lpage>17</lpage>.</mixed-citation></ref><ref id="CIT0088"><label>88.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>J</given-names></string-name>, <string-name><surname>Cai</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>M</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Li</surname><given-names>H</given-names></string-name>, <string-name><surname>Tan</surname><given-names>Z</given-names></string-name>. <article-title>Oxymatrine promotes S-Phase arrest and inhibits cell proliferation of human breast cancer cells in vitro through mitochondria-mediated apoptosis</article-title>. <source><italic toggle="yes">Biol Pharm Bull</italic></source>. <year>2017</year>;<volume>40</volume>:<fpage>1232</fpage>–<lpage>1239</lpage>. doi:<pub-id pub-id-type="doi">10.1248/bpb.b17-00010</pub-id><pub-id pub-id-type="pmid">28769005</pub-id></mixed-citation></ref><ref id="CIT0089"><label>89.</label><mixed-citation publication-type="journal"><string-name><surname>Lin</surname><given-names>B</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>L</given-names></string-name>. <article-title>Oxymatrine mediates Bax and Bcl-2 expression in human breast cancer MCF-7 cells</article-title>. <source><italic toggle="yes">Pharmazie</italic></source>. <year>2016</year>;<volume>71</volume>:<fpage>154</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">27183711</pub-id></mixed-citation></ref><ref id="CIT0090"><label>90.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Piao</surname><given-names>B</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, et al. <article-title>Oxymatrine diminishes the side population and inhibits the expression of beta-catenin in MCF-7 breast cancer cells</article-title>. <source><italic toggle="yes">Med Oncol</italic></source>. <year>2011</year>;<volume>28</volume>(<issue>Suppl 1</issue>):<fpage>S99</fpage>–<lpage>S107</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12032-010-9721-y</pub-id><pub-id pub-id-type="pmid">21069479</pub-id></mixed-citation></ref><ref id="CIT0091"><label>91.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>XY</given-names></string-name>, <string-name><surname>Xu</surname><given-names>WR</given-names></string-name>, <string-name><surname>Pei</surname><given-names>YX</given-names></string-name>, <string-name><surname>Lin</surname><given-names>HS</given-names></string-name>. <article-title>The research of Oxymatrine inhibits the proliferation of human breast cancer MCF-7 cells</article-title>. <source><italic toggle="yes">Mod Oncol</italic></source>. <year>2014</year>;<volume>22</volume>:<fpage>494</fpage>–<lpage>497</lpage>.</mixed-citation></ref><ref id="CIT0092"><label>92.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhu</surname><given-names>XY</given-names></string-name>, <string-name><surname>Xu</surname><given-names>WR</given-names></string-name>, <string-name><surname>Pei</surname><given-names>YX</given-names></string-name>, <string-name><surname>Lin</surname><given-names>HS</given-names></string-name>. <article-title>Oxymatrine diminished the side population and inhibited Wnt/β-catenin signaling pathway in MCF-7 breast cancer cells</article-title>. <source><italic toggle="yes">Chin J Integr Med</italic></source>. <year>2016</year>;<volume>36</volume>:<fpage>1504</fpage>–<lpage>1509</lpage>.</mixed-citation></ref><ref id="CIT0093"><label>93.</label><mixed-citation publication-type="journal"><string-name><surname>Lv</surname><given-names>JY</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>Y</given-names></string-name>. <article-title>Oxymatrine reverses multidrug resistance on breast cancer MCF-7/ADR cells</article-title>. <source><italic toggle="yes">China Mod Doctor</italic></source>. <year>2010</year>;<volume>48</volume>:<fpage>86</fpage>–<lpage>87</lpage>.</mixed-citation></ref><ref id="CIT0094"><label>94.</label><mixed-citation publication-type="journal"><string-name><surname>Chen</surname><given-names>DL</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Q</given-names></string-name>, <string-name><surname>Li</surname><given-names>Z</given-names></string-name>. <article-title>Oxymatrine enhances sensibility of MCF-7 cells to cytotoxicity of NK-92MI cells</article-title>. <source><italic toggle="yes">Chin J Immunol</italic></source>. <year>2019</year>;<volume>35</volume>:<fpage>680</fpage>–<lpage>685</lpage>.</mixed-citation></ref><ref id="CIT0095"><label>95.</label><mixed-citation publication-type="journal"><string-name><surname>Albini</surname><given-names>A</given-names></string-name>, <string-name><surname>Dell’Eva</surname><given-names>R</given-names></string-name>, <string-name><surname>Vene</surname><given-names>R</given-names></string-name>, et al. <article-title>Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets</article-title>. <source><italic toggle="yes">FASEB J</italic></source>. <year>2006</year>;<volume>20</volume>:<fpage>527</fpage>–<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.1096/fj.05-5128fje</pub-id><pub-id pub-id-type="pmid">16403733</pub-id></mixed-citation></ref><ref id="CIT0096"><label>96.</label><mixed-citation publication-type="journal"><string-name><surname>Luo</surname><given-names>H</given-names></string-name>, <string-name><surname>Rankin</surname><given-names>GO</given-names></string-name>, <string-name><surname>Liu</surname><given-names>L</given-names></string-name>, <string-name><surname>Daddysman</surname><given-names>MK</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>BH</given-names></string-name>, <string-name><surname>Chen</surname><given-names>YC</given-names></string-name>. <article-title>Kaempferol inhibits angiogenesis and VEGF expression through both HIF dependent and independent pathways in human ovarian cancer cells</article-title>. <source><italic toggle="yes">Nutr Cancer</italic></source>. <year>2009</year>;<volume>61</volume>:<fpage>554</fpage>–<lpage>563</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01635580802666281</pub-id><pub-id pub-id-type="pmid">19838928</pub-id></mixed-citation></ref><ref id="CIT0097"><label>97.</label><mixed-citation publication-type="journal"><string-name><surname>Priyadarsini</surname><given-names>RV</given-names></string-name>, <string-name><surname>Vinothini</surname><given-names>G</given-names></string-name>, <string-name><surname>Murugan</surname><given-names>RS</given-names></string-name>, <string-name><surname>Manikandan</surname><given-names>P</given-names></string-name>, <string-name><surname>Nagini</surname><given-names>S</given-names></string-name>. <article-title>The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumors</article-title>. <source><italic toggle="yes">Nutr Cancer</italic></source>. <year>2011</year>;<volume>63</volume>:<fpage>218</fpage>–<lpage>226</lpage>. doi:<pub-id pub-id-type="doi">10.1080/01635581.2011.523503</pub-id><pub-id pub-id-type="pmid">21294050</pub-id></mixed-citation></ref><ref id="CIT0098"><label>98.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhuo</surname><given-names>XB</given-names></string-name>, <string-name><surname>Hu</surname><given-names>YP</given-names></string-name>, <string-name><surname>Zheng</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>QJ</given-names></string-name>. <article-title>A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways</article-title>. <source><italic toggle="yes">Mol Cell Biochem</italic></source>. <year>2018</year>;<volume>449</volume>:<fpage>47</fpage>–<lpage>54</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11010-018-3341-9</pub-id><pub-id pub-id-type="pmid">29532226</pub-id></mixed-citation></ref><ref id="CIT0099"><label>99.</label><mixed-citation publication-type="journal"><string-name><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name><surname>Wang</surname><given-names>G</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, et al. <article-title>Synthesis and biological evaluation of matrine derivatives containing benzo-alpha-pyrone structure as potent anti-lung cancer agents</article-title>. <source><italic toggle="yes">Sci Rep</italic></source>. <year>2016</year>;<volume>6</volume>:<fpage>35918</fpage>. doi:<pub-id pub-id-type="doi">10.1038/srep35918</pub-id><pub-id pub-id-type="pmid">27786281</pub-id></mixed-citation></ref><ref id="CIT0100"><label>100.</label><mixed-citation publication-type="journal"><string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Qi</surname><given-names>Y</given-names></string-name>, <string-name><surname>Bai</surname><given-names>ZH</given-names></string-name>, et al. <article-title>A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways</article-title>. <source><italic toggle="yes">Acta Pharmacol Sin</italic></source>. <year>2017</year>;<volume>38</volume>:<fpage>120</fpage>–<lpage>132</lpage>. doi:<pub-id pub-id-type="doi">10.1038/aps.2016.104</pub-id><pub-id pub-id-type="pmid">27773936</pub-id></mixed-citation></ref><ref id="CIT0101"><label>101.</label><mixed-citation publication-type="journal"><string-name><surname>Yin</surname><given-names>H</given-names></string-name>, <string-name><surname>Que</surname><given-names>R</given-names></string-name>, <string-name><surname>Liu</surname><given-names>C</given-names></string-name>, et al. <article-title>Survivin-targeted drug screening platform identifies a matrine derivative WM-127 as a potential therapeutics against hepatocellular carcinoma</article-title>. <source><italic toggle="yes">Cancer Lett</italic></source>. <year>2018</year>;<volume>425</volume>:<fpage>54</fpage>–<lpage>64</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.canlet.2018.03.044</pub-id><pub-id pub-id-type="pmid">29608986</pub-id></mixed-citation></ref><ref id="CIT0102"><label>102.</label><mixed-citation publication-type="journal"><string-name><surname>Sun</surname><given-names>M</given-names></string-name>, <string-name><surname>Han</surname><given-names>J</given-names></string-name>, <string-name><surname>Duan</surname><given-names>J</given-names></string-name>, et al. <article-title>Novel antitumor activities of Kushen flavonoids in vitro and in vivo</article-title>. <source><italic toggle="yes">Phytother Res</italic></source>. <year>2007</year>;<volume>21</volume>:<fpage>269</fpage>–<lpage>277</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ptr.2066</pub-id><pub-id pub-id-type="pmid">17186494</pub-id></mixed-citation></ref><ref id="CIT0103"><label>103.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>WL</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>JD</given-names></string-name>, et al. <article-title>Synthesis, structure-activity relationship and biological evaluation of anticancer activity for novel N-substituted sophoridinic acid derivatives</article-title>. <source><italic toggle="yes">Bioorg Med Chem Lett</italic></source>. <year>2011</year>;<volume>21</volume>:<fpage>5251</fpage>–<lpage>5254</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bmcl.2011.07.038</pub-id><pub-id pub-id-type="pmid">21807514</pub-id></mixed-citation></ref><ref id="CIT0104"><label>104.</label><mixed-citation publication-type="journal"><string-name><surname>Zhang</surname><given-names>XL</given-names></string-name>, <string-name><surname>Cao</surname><given-names>MA</given-names></string-name>, <string-name><surname>Pu</surname><given-names>LP</given-names></string-name>, et al. <article-title>A novel flavonoid isolated from Sophora flavescens exhibited anti-angiogenesis activity, decreased VEGF expression and caused G0/G1 cell cycle arrest in vitro</article-title>. <source><italic toggle="yes">Pharmazie</italic></source>. <year>2013</year>;<volume>68</volume>:<fpage>369</fpage>–<lpage>375</lpage>.<pub-id pub-id-type="pmid">23802436</pub-id></mixed-citation></ref><ref id="CIT0105"><label>105.</label><mixed-citation publication-type="journal"><string-name><surname>Bi</surname><given-names>C</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, et al. <article-title>Synthesis and biological evaluation of sophoridinol derivatives as a novel family of potential anticancer agents</article-title>. <source><italic toggle="yes">ACS Med Chem Lett</italic></source>. <year>2014</year>;<volume>5</volume>:<fpage>1225</fpage>–<lpage>1229</lpage>. doi:<pub-id pub-id-type="doi">10.1021/ml500289h</pub-id><pub-id pub-id-type="pmid">25408835</pub-id></mixed-citation></ref><ref id="CIT0106"><label>106.</label><mixed-citation publication-type="journal"><string-name><surname>Bi</surname><given-names>C</given-names></string-name>, <string-name><surname>Ye</surname><given-names>C</given-names></string-name>, <string-name><surname>Li</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name><surname>Shao</surname><given-names>R</given-names></string-name>, <string-name><surname>Song</surname><given-names>D</given-names></string-name>. <article-title>Synthesis and biological evaluation of 12-N-p-chlorobenzyl sophoridinol derivatives as a novel family of anticancer agents</article-title>. <source><italic toggle="yes">Acta Pharmaceutica Sinica B</italic></source>. <year>2016</year>;<volume>6</volume>:<fpage>222</fpage>–<lpage>228</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.apsb.2016.03.004</pub-id><pub-id pub-id-type="pmid">27175333</pub-id></mixed-citation></ref><ref id="CIT0107"><label>107.</label><mixed-citation publication-type="journal"><string-name><surname>Jiang</surname><given-names>L</given-names></string-name>, <string-name><surname>Wu</surname><given-names>L</given-names></string-name>, <string-name><surname>Yang</surname><given-names>F</given-names></string-name>, et al. <article-title>Synthesis, biological evaluation and mechanism studies of matrine derivatives as anticancer agents</article-title>. <source><italic toggle="yes">Oncol Lett</italic></source>. <year>2017</year>;<volume>14</volume>:<fpage>3057</fpage>–<lpage>3064</lpage>. doi:<pub-id pub-id-type="doi">10.3892/ol.2017.6475</pub-id><pub-id pub-id-type="pmid">28927053</pub-id></mixed-citation></ref><ref id="CIT0108"><label>108.</label><mixed-citation publication-type="journal"><string-name><surname>Li</surname><given-names>ZY</given-names></string-name>, <string-name><surname>Huang</surname><given-names>WC</given-names></string-name>, <string-name><surname>Tu</surname><given-names>RS</given-names></string-name>, <string-name><surname>Gu</surname><given-names>RY</given-names></string-name>, <string-name><surname>Lin</surname><given-names>CF</given-names></string-name>, <string-name><surname>Liou</surname><given-names>CJ</given-names></string-name>. <article-title>Sophoraflavanone G induces apoptosis in human leukemia cells and blocks MAPK activation</article-title>. <source><italic toggle="yes">Am J Chin Med (Gard City N Y)</italic></source>. <year>2016</year>;<volume>44</volume>:<fpage>165</fpage>–<lpage>176</lpage>. doi:<pub-id pub-id-type="doi">10.1142/S0192415X16500117</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000883 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000883 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7051174
|texte= Anti-Tumor Activities of Bioactive Phytochemicals in Sophora flavescens for Breast Cancer
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:32161498" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |